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ABSTRACT 
 
 
 There is an ever increasing need to develop new antimicrobial agents with novel 
mechanisms of action.  These new agents will help to combat the steady rise of antibiotic-
resistant bacteria which are becoming more and more difficult to treat due to the 
dwindling number of antibiotics available to treat such organisms.  This body of work 
brings to light the many ways in which medicinal chemistry plays a vital role in the 
discovery of novel antimicrobial agents.  Chapter 1 is an introduction into antimicrobial 
agents.  It provides a brief history of the discovery of antimicrobial agents, and delves 
into reasons why new agents are urgently needed.  It also examines the recent 
antimicrobial agents approved by the Food and Drug Administration for use in the United 
States, and looks into the current antimicrobial drug pipeline.  Chapter 2 explores the 
current therapy regime for combating tuberculosis and expresses the need for novel 
agents in this arena.  It also shows how current medicinal chemistry techniques are being 
utilized to develop a novel class of potential anti-tuberculosis agents with novel 
mechanisms of action.  Chapter 3 discusses the treatment of gram-negative bacterial 
infections with novel hybrid antimicrobial agents.  These agents afford current 
antimicrobial agents, which have difficulty penetrating the gram-negative cell wall, a way 
into the gram-negative cell in order to exert their intended mechanism of action.  This 
chapter explores the rationale and design behind the making of such agents.  Chapter 4 
provides an overview of the work detailed in the dissertation; as well as future directions 
that will help further the scope of these projects.   
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CHAPTER 1: INTRODUCTION 
 
 
Introduction to Antibacterial Agents 
 
 Infectious diseases have been one of the greatest blights in the history of 
humanity.1  It was not until the discovery of the first antibacterial agent in the 1930s that 
a glimmer of hope was seen.  That agent was Prontosil, and it was discovered by Gerhard 
Domagk in 1935.1-3  Prontosil was later found to be a prodrug that was metabolized in 
vivo to its active metabolite sulfanilamide (Figure 1.1).4  Prontosil was the first of the 
“sulfa” drugs discovered, and its discovery ushered in the era of antibiotics.   
 
 Antibacterial agents, or antibiotics, are a class of a much larger group of 
compounds called antimicrobial agents.  Antibiotics used to refer to only naturally 
occurring molecules produced by a variety of microorganisms.5 However, the term has 
evolved to include man-made synthetic compounds as well.6  Antibiotics can be broken 
down into four distinct classes based upon their mechanism of action.  Those four classes 
are (1) the agents that inhibit bacterial cell wall biosynthesis, (2) the agents that inhibit 
protein biosynthesis, (3) the agents that inhibit deoxyribonucleic acid (DNA) or 
ribonucleic acid (RNA) synthesis, and (4) the agents that inhibit folate synthesis.6 
 
 
Inhibitors of Bacterial Cell Wall Biosynthesis 
 
 The bacterial cell wall plays a vital role in the survival and proliferation of the 
bacteria.  There are also substantial differences between the mammalian cell wall and the 
bacterial cell wall, thus creating an attractive target for bacterial chemotherapy.  This 
class of antibiotics contains two families of compounds that act upon various targets 
within the biosynthetic cascade of cell wall formation.  Those two families are the β-
lactams and the glycopeptides.   
 
β-lactams 
 
 This family of compounds is comprised of four groups of molecules: (1) the 
penicillins, (2) the cephalosporins, (3) the carbapenems, and (4) the monobactams (Figure 
1.2).  This family of compounds all act via the same mechanism of action, and that is by 
binding and inhibiting the penicillin binding proteins (PBPs); more specifically they 
inhibit peptidoglycan transpeptidase causing lysis and cell death.1,6  The core structure of 
this family consists of an β-lactam core, which contains a carbonyl lactam structure this is 
essential for the activity of these molecules.1,7  To differentiate the various groups of 
molecules within this family, one must look at the ring that is fused to the β-lactam core.1  
The first group of molecules is the penicillins, and they contain a saturated pentacyclic 
ring system fused to the core ring structure.   
 
The penicillins have been greatly modified from the initial compound isolated, 
Penicillin G.  These modifications occur off of the carbonyl position on the amide side  
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Figure 1.1: Activation of Prontosil to Sulfanilamide 
 
 
 
 
 
 
Figure 1.2:  General Structures of the Four Classes of β-Lactam Antibiotics 
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2 
chain.8  The modifications have been made in an effort to improve the potency, oral 
bioavailability, antibacterial spectrum of activity, and decrease sensitivity to β-
lactamases.9   
 
The next group of molecules in this family are the cephalosporins.  This group is 
recognized by its unsaturated hexacyclic ring structure attached to the azetidinone core.  
The cephalosporins are the most widely prescribed and largest-selling group of the β-
lactams.6  Since their discovery in the 1960s, thousands of derivatives have been 
synthesized in an effort to increase the spectrum of activity and decrease the β-lactamase 
susceptibility of this group of compounds.1,5   
 
The carbapenems are recognized by their unsaturated pentacyclic ring structure 
attached to the core β-lactam structure.  These molecules exhibit a broad spectrum of 
activity, but have low oral bioavailability.1,5,10,11  This group of molecules possesses an 
added benefit of being resistant to most β-lactamases, thus increasing their potency and 
spectrum of action.6,9   
 
The final group of molecules in this family are the monobactams.  These 
molecules are very easy to identify due to the fact that they only possess azetidinone core 
with no other fused ring system.  These compounds are only active against gram negative 
pathogens, with good activity against P. aeruginosa.6,12-16  These molecules have a 
similar mechanism of action as the other β-lactam antibiotics, but they possess a 
specificity for PBP3 and can be complementary to other β-lactams.6,9   
 
Glycopeptides and Lipoglycopeptides 
 
 This family of compounds was first discovered with vancomycin in 1956, and 
was later expanded to include lipoglycopeptides by Lancini in 1989 after the discovery of  
teicoplanin in 1978 (Figure 1.3).1,17  The mechanism of action of the family differs 
slightly from that of the β-lactams.  The glycopeptides are able to cross the bacterial cell 
wall of gram-positive bacteria and bind to the terminal D-ala-D-ala dipeptide of the 
peptidoglycan precursor.  The steric hindrance caused by these molecules blocks two key 
enzymatic reactions of peptidoglycan synthesis, transglycosylation and transpeptidation, 
ultimately causing inhibition of growth and death.1  These compounds are reserved as 
drugs of last resort due to their excellent activity against gram-positive bacteria, 
especially methicillin-resistant Staphylococcus aureus (MRSA).18   
 
 
Inhibitors of Protein Biosynthesis 
 
 This class of compounds exert their antibacterial action by blocking one or more 
of the steps in protein biosynthesis that occur on either the 30S or 50S subunits of the 
bacterial ribosome.  There are a number of families of molecules that make up this family 
including the macrolides, lincosamides, streptogramins, oxazolidinones, 
aminoglycosides, and tetracyclines.6  However, the major families that compose this  
3 
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Figure 1.3:  Structures of Vancomycin and Teicoplanin
4 
family are the aminoglycosides, macrolides, and tetracylines.  Therefore these three 
groups will be discussed further in this section. 
 
Aminoglycosides 
 
  This family of molecules all contain a pharmacophoric 1,3-diaminoinositol 
moiety (Figure 1.4).5  This family of compounds acts on the 30S ribosomal subunit, more 
specifically the 16S ribosomal ribonucleic acid (rRNA).19  Upon binding, they impair the 
proofreading ability of the ribosome; therefore causing mistranslation of RNA templates 
and consequent selection of wrong amino acids leading to the formation of nonsense 
proteins.5  This prevents the proper joining of the 30S and 50S ribosomal subunits 
leading to the inhibition of protein synthesis.  These antibiotics are structurally diverse, 
and it has been suggested that the name of this family change to aminocyclitols in order 
to encompass the wide array of structures found in this class.20  These agents alone show 
potent activity against gram-negative bacteria, but lack potent activity against most gram-
positive bacteria.  However, they are used in combination with β-lactams to treat some 
enterococcal infections.6,8   
 
Macrolides 
 
 The name for this family of molecules is derived from the large lactone, cyclic 
ester, ring structure found in each of these compounds (Figure 1.5).5  These compounds 
exert their antibacterial action by binding reversibly to the 50S ribosomal subunit and 
preventing protein elongation by blocking peptidyltransferase from forming peptide 
bonds between amino acids.21,22  These agents also block the assembly of the 50S 
ribosomal subunit through an interaction with the 23S rRNA.23  A new derivation of this 
family has recently been discovered and approved for use in the United States, and they 
are the ketolides.  In this subfamily, the 3-OH is oxidized to a ketone, thus removing the 
site of attachment of the cladinose sugar.24  This entire family of agents is considered 
broad-spectrum antibiotics, especially as newer agents continue to be developed. 
 
Tetracyclines 
 
 This family consists of molecules with a highly functionalized and partially 
reduced naphthacene (four linearly fused six-membered rings) ring system (Figure 1.6).5  
These agents work at the 30S ribosomal subunit and block the binding of incoming 
aminoacyl-transfer ribonucleic acid (t-RNA) to the A site resulting in termination of 
peptide chain elongation.5,6  This family of antibiotics are classified as broad-spectrum.  
However, due to their adverse side effects (staining of teeth and impairment of bone 
structure development) they are rarely the drug of choice for treatment, especially for 
children.5,25 
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Figure 1.4:  Structures of Aminoglycoside Antibiotics 
 
 
 
 
 
Figure 1.5:  Structures of Macrolide and Ketolide Antibiotics 
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Figure 1.6:  Structure of Tetracycline  
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Inhibitors of DNA and RNA Synthesis 
 
This class of antibiotics works on one of three targets: DNA gyrase, 
topoisomerase IV, or DNA-directed RNA polymerase.  There are two families of 
antibiotics included within this class, and those are the quinolones and the rifamycins.  
The activity of the quinolones (Figure 1.7) is derived from their inhibition of DNA gyrase 
and topoisomerase IV.5  While DNA gyrase and topoisomerase IV have similar 
mechanisms of action, the difference is the fact that DNA gyrase is more important for 
gram-negative organisms and topoisomerase IV is more important for gram-positive 
organisms.9,26  The quinolones work by binding to DNA gyrase or topoisomerase IV and 
preventing the supercoiling of DNA, thereby inhibiting synthesis of DNA.6  The 
quinolones were not widely used until the discovery of the fluoroquinolones in the 
1980s.27  There are currently four generations of quinolones that have been developed 
and are in clinical use. 
 
The rifamycin family of antibiotics works on DNA-directed RNA polymerase.  
These agents bind to the β-subunit of DNA-directed RNA polymerase and inhibit the 
initiation of chain formation in RNA synthesis.6  Rifamycin is a natural product with 
several natural analogs, but three semisynthetic analogs have since been synthesized. 
Those agents are rifampin (Figure 1.8), rifabutin, and rifapentine.  These agents are front-
line agents in the treatment of tuberculosis. 
 
 
Inhibitors of Folate Synthesis 
 
Folate is critical to the survival of all living organisms.28  It plays a role in DNA 
synthesis by serving in the transfer of methyl, formyl, and other single-carbon fragments 
in the biosynthesis of purine nucleotides.29  Humans and bacteria obtain folate via 
different routes. Humans obtain folate through their diet, while bacteria synthesis folate 
through the folate biosynthetic pathway.  This difference makes the folate biosynthetic 
pathway a very attractive drug target.28  There are two enzymes in this pathway that are 
currently targeted by antibacterial agents: dihydropteroate synthesis (DHPS) and 
dihydrofolate reductase (DHFR).  The family of agents that act on DHPS is the 
sulfonamides. DHFR is acted upon by a single agent, and that is trimethoprim.5 
 
Sulfonamides 
 
The sulfonamides work by inhibiting DHPS, which catalyses the conversion of p-
aminobenzoic acid (PABA) to dihydroteroate.30,31  Due to resistance issues, most of the 
originally developed sulfonamide drugs are no longer in use as a monotherapy.  
However, there are some still in use for acne and urinary tract infections.  The most 
commonly used drug is in this class is sulfamethoxazole (Figure 1.9).  This agent is often 
used in combination with trimethoprim, which expands it antibacterial spectrum and 
reduces the potential for the development of drug resistance.9 
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Figure 1.8:  Structure of Rifampin 
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Figure 1.9:  Structure of Sulfamethoxazole 
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Trimethoprim   
 
Trimethoprim works by inhibiting DHFR, which converts dihydrofolate into 
tetrahydrofolate.32  This enzyme is found in humans as well as bacteria, thus it is 
important that trimethoprim selectively inhibit the bacterial form of the enzyme.  It is 
found that trimethoprim inhibits bacterial DHFR at a much lower concentration than the 
human DHFR, thus providing the basis for its selectivity.5  While trimethoprim (Figure 
1.10) is often used in combination with sulfamethoxazole, it can also be utilized as a 
standalone agent.33 
 
 
The Need for Novel Antibacterial Agents 
 
The prevalence of drug resistant bacteria is growing at an alarming rate in both 
developing and developed countries.34  From this statement alone, it should be clear that 
the need for the development of novel antibacterial agents is of utmost importance.  In the 
current antibacterial drug pipeline, there is only a miniscule glimmer of hope.34-38  This 
rapid increase in resistant bacteria coupled with the slow development of novel agents 
has lead some experts to call this time the “dawn of the post-antibiotic era.”39-41   
 
There exists a perpetual need for new antibiotics.  Most drugs will be just as 
effective in the future as they are today, but that is not the case with antibiotics.  
Eventually, the inevitable rise of resistance will erode the utility of today’s antibiotics.6,36  
There are three factors that intensify this supply problem by discouraging antibiotic 
development.42  First, antibiotics are used in smaller quantities than other drugs.  The 
standard antibiotic course lasts only weeks compared to treatment for chronic illness 
which can last a lifetime.  Therefore, antibiotics yield lower revenues than most drugs.  
Second, the use of newly approved antibiotics is often limited to serious bacterial 
infections.  The third reason is an increase in regulatory requirements to get a drug 
licensed, which makes clinical trials cost prohibitive.  However, most newly approved 
drugs can be prescribed to all who may benefit from their use.  These factors ultimately 
result in this quandary: Resistance is on the rise while antibiotic discovery and 
development are on the decline.36,43,44 
 
Three classes of antibiotic-resistant pathogens are emerging as major threats to 
public health.  The first pathogen of concern is MRSA.  It is estimated that MRSA is 
responsible for approximately 19,000 deaths per year in the United States.  The rising 
prevalence of MRSA increases the likelihood that vancomycin-resistant Staphylococcus 
aureus (VRSA), which is just as deadly as MRSA but more challenging to treat, will 
become a major concern in hospitals.45,46  The second class of pathogens are multidrug-
resistant (MDR) and pandrug-resistant (PDR) gram-negative bacteria.  These bacteria 
may be less prevalent than MRSA, but they pose a severe risk of infections that are truly 
untreatable.  These strains of Acinetobacter baumannii, Esherichia coli, Klebsiella 
pneumonia, and Pseudomonas aeruginosa are resistant to some (MDR) or all (PDR) of 
the antibiotics used to treat gram-negative bacteria: penicillins, cephalosporins, 
carbamenems, monobactams, quinolones, aminoglycosides, tetracyclines, and  
11 
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12 
polymixins.47   The third class of pathogens are MDR and extensively drug-resistant 
(XDR) strains of Mycobacterium tuberculosis.  These strains are an ever increasing threat 
in developing nations.48  MDR-TB treatments requires a 2-year course of antibiotics with 
serious side effects; XDR-TB is even more difficult to treat and often fatal.49 
 
The number of new antibiotic agents approved by the Food and Drug 
Administration (FDA) has fallen steadily since 1980.39  It is also pertinent to note that 
during that time 75 percent of the drugs approved were in two classes, beta-lactams and 
quinolones.  Between 1935 and 1968 there were 14 classes of antibiotics introduced for 
human used; since then, only five have been introduced.  Those five classes are; the 
oxazolidinones, lipopeptides, glycylcyclins, pleuromutilins, and mupirocin.39  While most 
new antibiotics come from existing classes, there is now more diversity within these 
classes.  Also, these new agents may be more effective and safer than earlier drugs in 
their class.50 
 
 
New Antibiotics 
 
 The FDA is the approving body for new antibiotics in the United States.  Once a 
new drug has the approval of the FDA, it can be sold for use in the United States.  Since 
1998, the FDA has approved a number of new antibiotics.  However, only a limited 
number of these agents possess a novel mechanism of action.  Having new antibiotics 
approved for use is a great thing, but those antibiotics which utilize the same mechanism 
of action as previously approved drugs always run the risk of increasing the rate of 
resistance.  Drugs possessing a novel mechanism of action are greatly needed to help 
alleviate this burden.   
 
 
Recently Approved Antibiotics 
 
This section contains a list and description of each new antibacterial agent that 
has been approved since 2000.39 
 
Linezolid 
 
 This drug is sold under the brand name Zyvox (Figure 1.11).  It was approved for 
use by the FDA in 2000.  Sales of this drug are now over $1 billion dollars per year.  It is 
approved to treat VRE infections, as well as hospital- and community-acquired 
pneumonia and cSSTI caused by gram-positive organisms; including methicillin-resistant 
Staphylococcus aureus (MRSA).  This is the first and only commercially available drug 
in the oxazolidinone class.  This is a new class of antibiotics which acts by inhibiting 
protein synthesis in a novel way compared to currently known mechanisms of other 
antibiotics. 
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Figure 1.11: Structure of Linezolid 
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Cefditoren 
 
 Sold under the brand name Spectracef, it was approved for use by the FDA in 
2001 (Figure 1.12).  It is approved for the treatment of bronchitis and community-
acquired pneumonia caused by drug-susceptible gram-positive and gram-negative 
organisms.  It is also used to treat uncomplicated skin- and soft-tissue infections caused 
by MSSA, as well as pharyngitis and tonsillitis caused by Streptococcus pyogenes.  This 
drug is a third generation cephalosporin antibiotic. 
 
Ertapenem 
 
 This drug is sold under the brand name Invanz (Figure 1.13).  It was approved by 
the FDA in 2001.  It can be used to treat intra-abdominal infections, community-acquired 
pneumonia, urinary tract infections, cSSTI, and acute pelvic infections caused by gram-
positive and gram-negative organisms.  However, it lacks activity against Pseudomonas 
aeruginosa.  This drug belongs to the carbapenem class of antibiotics. 
 
Gemifloxacin 
 
 Sold under the brand name Factive (Figure 1.14), it was approved for use by the 
FDA in 2003.  It is approved for the treatment of community-acquired pneumonia and 
bronchitis caused by gram-positive and gram-negative organisms; including multi-drug 
resistant Streptococcus pneumoniae.  This drug belongs to the fluoroquinolone class of 
antibiotics. 
 
Daptomycin 
 
 This drug is sold under the brand name Cubicin (Figure 1.15).  It was approved 
for use by the FDA in 2003.  Sales of this drug have reached over $600 million dollars 
per year in the United States.  It is approved for the treatment of cSSTI and bacteremia 
caused by gram-positive bacteria; including MRSA.  Daptomycin belongs to the new 
lipopeptide class of antibiotics.  It presents a novel mechanism of action by disrupting 
multiple aspects of bacterial cell membrane function. 
 
Telithromycin 
 
 Sold under the brand name Ketek, telithromycin (Figure 1.16) was approved for 
use by the FDA in 2004.  It is approved for use in the treatment of community-acquired 
pneumonia caused by gram-positive and gram-negative bacteria; including multi-drug 
resistant strains of Streptococcus pneumoniae.  When first approved by the FDA, 
telithromycin was approved for use in treating numerous bacterial infections.  However, 
due to safety issues with the drug, the FDA removed its approval to treat some infections 
and issued a black box warning for the drug in 2007 stating that patients with myasthenia 
gravis should not take this drug.51  Telithromycin is the first ketolide antibiotic to enter 
clinical use. 
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Figure 1.14: Structure of Gemifloxacin 
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Figure 1.16: Structure of Telithromycin 
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Tigecycline 
 
 Tigecycline is sold under the brand name Tygacil (Figure 1.17).  It was approved 
by the FDA in 2005.  It is used for the treatment of cSSTI and intra-abdominal infections 
caused by gram-positive and gram-negative bacteria; including MRSA.  This agent 
belongs to the recently discovered glycylcycline subclass of tetracycline antibiotics. 
 
Retapamulin 
 
 This drug is sold under the brand name Altabax (Figure 1.18).  It was approved 
for use by the FDA in 2007.  This agent is only approved for topical use in the treatment 
of impetigo caused by gram-positive infections.  This drug is the first drug in the new 
class of pleuromutilin antibiotics to be approved for human use. 
 
Doripenem 
 
 Sold under the brand name Doribax, Doripenem (Figure 1.19) was approved for 
use by the FDA in 2007.  It is approved for the treatment of intra-abdominal infections 
and urinary tract infections caused by gram-positive and gram-negative bacteria.  This 
agent is an ultra-broad spectrum injectable antibiotic belonging to the carbapenem class 
of antibiotics.  It shows very good efficacy against Pseudomonas aeruginosa. 
 
Telavancin 
 
 Telavancin is sold under the brand name Vibativ (Figure 1.20).  It was approved 
for use by the FDA in 2009.  It is approved for the treatment of cSSTI caused by gram-
positive bacteria; including MRSA.  Telavancin is a member of the lipoglycopeptide 
class of antibiotics, and is a synthetic derivative of vancomycin. 
 
 
Antibiotics in the Pipeline: Gram-Positive 
 
 This section contains information about agents that are currently in the pipeline 
for the treatment of gram-positive bacteria.35  In the current antibiotic pipeline, there are 
numerous potentially new agents that can be utilized to treat bacterial infections.  The 
majority of those agents are aimed at treating infections caused by gram-positive 
organisms.  A high percentage of these agents build upon previously known antibiotic 
groups.  However, there are a handful of novel agents coming through the pipeline which 
have novel scaffolds and/or novel mechanisms of action.  
  
Oritavancin 
 
 Oritavancin (Figure 1.21) is in the final stages of approval by the FDA.  It has 
been temporarily rejected by the ruling body pending further clinical investigations into 
its safety profile.  It belongs to the glycopeptides family of antibiotics, and is pending 
approval for the treatment of cSSTI. 
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Figure 1.20: Structure of Telavancin 
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Iclaprim 
 
 This agent is currently under review by the FDA, but the FDA has ruled that it is 
not approvable in its current form.  Iclaprim (Figure 1.22) is a 2,4-Diaminopyrimidine 
(structurally related to trimethoprim) which acts as a dihydrofolate reductase inhibitor.  It 
is pending approval for the treatment of cSSTI. 
 
Ceftobiprole 
 
 Ceftobiprole (Figure 1.23) is currently under review by the FDA, but the FDA has 
deemed that further clinical-site audits are necessary before a final review can be 
obtained.  Ceftobiprole is a fifth-generation cephalosporin.  This agent is being reviewed 
for the treatment of cSSTI; including diabetic foot infections.  It is also currently 
undergoing Phase 3 clinical trials for the treatment of hospital-acquired pneumonia and 
severe community-acquired pneumonia.  This agent is notable for its activity against 
MRSA. 
 
Cethromycin 
 
 This agent is currently under review by the FDA (Figure 1.24).  The FDA has 
deemed that further clinical site studies are needed in order for an approval to be 
obtained.  This agent belongs to the macrolide subclass of antibiotics known as ketolides.  
It is being investigated for effectiveness against community-acquired pneumonia and 
against biodefense pathogens such as anthrax, plague, tularemia, and melloidosis.   
 
Ceftaroline 
 
 This has completed Phase 3 clinical trials for the treatment of cSSTI and is 
currently in Phase 3 trials for the treatment of community-acquired pneumonia.  It is a 
fifth-generation cephalosporin (Figure 1.25).  This agent also shows promising activity 
against MRSA. 
 
Fidaxomicin 
 
 This agent is currently undergoing Phase 3 clinical trials for the treatment of 
Clostridium difficile-associated diseases (Figure 1.26).  This agent represents a new class 
of antibiotics for the treatment of these diseases; RNA polymerase inhibitor. 
 
Ramoplanin 
 
 This agent is currently undergoing Phase 2/3 trials for the treatment of 
Clostridium difficile-associated diseases resistant to vancomycin/metronidazole (Figure 
1.27).  It belongs to the glycolipdepsipeptide class of antibiotics and works by inhibiting 
cell wall biosynthesis.  It has been fast-tracked by the FDA in hopes to expedite its 
approval. 
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Pagibaximab 
 
 Pagibaximab is a chimeric monoclonal antibody against lipoteichoic acid.  This 
agent represents an agent with a novel mechanism of action in the treatment of bacterial 
infections.  It is currently undergoing Phase 2b/3 clinical trials as a staphylococcal 
prophylaxis in very low birth weight neonates. 
 
Phase 2 Completed 
 
 All of the agents discussed in the section have all completed Phase 2 clinical 
trials, but have not yet moved on to Phase 3.  The first agent is amadacycline (Figure 
1.28).  This drug is a tetracycline derivate, and is being investigated for the treatment of 
cSSTI, diabetic foot infections, and community-acquired pneumonia.  The second agent 
that has completed Phase 2 trials is delafloxacin (Figure 1.29).  It is a quinolone 
derivative that is being investigated for the treatment of cSSTI and community-acquired 
pneumonia.  The final agent that has completed Phase 2 clinical trials is V710.  This 
agent is a Staphylococcus aureus vaccine, which represents another novel mechanism of 
action in the treatment of gram-positive bacteria infections.  It is being considered for a 
single dose treatment for patients scheduled for cardiothoracic surgery and kidney disease 
patients. 
 
Phase 2 Ongoing 
 
There are a number of agents in the antibacterial pipeline that are currently in 
Phase 2 clinical trials.  The first agent is nemonoxacin.  It is a non-fluorinated quinolone 
that is being investigated for the treatment of community- and hospital-acquired 
pneumonia and diabetic foot infections.  The next agent, TD-1792, is a unique hybrid 
antibiotic.  It combines the potency and efficacy of vancomycin and a cephalosporin in 
one antibacterial agent.  It is targeted toward the treatment of cSSTI and bacteraemia.  
Radezolid (Figure 1.30) is the next agent currently undergoing Phase 2 clinical trials.   It 
is a member of the oxazolidinone class of antibiotics.  It is being tested for the treatment 
of mild-to-moderate community-acquired pneumonia and uncomplicated skin and soft 
tissue infections.  PZ-601 is another agent in the pipeline undergoing Phase 2 trials.  It is 
a carbapenem antibiotic that is being investigated for the treatment of cSSTI.   
 
The next agent undergoing Phase 2 trials is NXL 103.  This drug belongs to the 
streptogramin class of antibiotics.  It is a combination of the agents linopristin and 
floprisitin.  It is being investigated for the treatment of community-acquired pneumonia.  
Another agent currently undergoing Phase 2 trials is torezolid (Figure 1.31).  Torezolid is 
an oxazolidinone antibiotic that is being investigated for the treatment of cSSTI and 
hospital-acquired pneumonia.  WCK-771 is in Phase 2 clinical trials for the treatment of 
gram-positive infections.  It is a quinolone antibiotic.  More specifically, it is the active 
isomer of nadifloxacin.  Finally, zabofloxacin is a quinolone antibiotic in Phase 2 trials 
for the treatment of community-acquired respiratory infections. 
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Figure 1.28: Structure of Amadacycline 
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Figure 1.29: Structure of Delafloxacin 
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Figure 1.30: Structure of Radezolid 
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Figure 1.31: Structure of Torezolid 
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Phase 1 Completed 
 
 There are two agents that have completed Phase 1 clinical trials, but have yet to 
advance on to Phase 2.  The first agent is CEM-101.  This agent is an oral macrolide 
antibiotic that is being investigated for the treatment of community-acquired pneumonia.  
The second agent that has completed Phase 1 clinical trials is BC-3205.  This agent 
belongs to the pleuromutilin class of antibiotics, but unlike the current pleuromutilins 
which are topical agents, BC-3205 is an oral antibiotic.  It is being investigated for the 
treatment of cSSTI and community-acquired pneumonia. 
 
Phase 1 Ongoing 
 
 The agents in the section are currently involved in Phase 1 clinical trials.  The first 
agent is RWJ-416457 (Figure 1.32).  This agent belongs to the oxazolidinone class of 
antibiotics and is being investigated for the treatment of gram-positive infections.  The 
next drug is PMX-30063.  This is a very unique and novel agent.  It is classified as a 
small molecule mimetic of a host defense protein, defensin.  It is the first known small 
molecule mimetic of a host defense protein to enter human clinical trials for systemic use.  
This agent represents an entirely new class of antibiotic drugs.  It is being investigated for 
the treatment of staphylococcal infections.  The last two agents that are currently in Phase 
1 clinical trials both represent a novel class of antibiotics, fatty acid biosynthesis (Fab) 
inhibitors.52  The first agent is AFN-1252 (Figure 1.33), and it is a FabI inhibitor.  The 
second agent is platensimycin (Figure 1.34), and it is a FabF inhibitor.  Both of these 
agents are being investigated for the treatment of staphylococcal infections. 
 
 
Antibiotics in the Pipeline: Gram-Negative 
 
 Over the past several years, there has been a drastic increase in the number of 
multi-drug resistant isolates of gram-negative bacteria.53  The outlook for antibiotics that 
treat gram-negative infections is not as positive as in the gram-positive arena.  This is 
causing major concern within the scientific community.  There are currently no 
antibiotics being review for final approval by the FDA.  There are not even any agents 
currently in Phase 3 clinical trials.  This is a major issue because without any agents that 
have advanced past Phase 2 clinical trials, it will be at least 5 years before the first agent 
becomes routinely available in the clinic.  While most of the agents in the pipeline are 
modifications of existing classes of antibiotics, there are a few novel classes rising 
through the pipeline as well.  Given the widespread resistance problem and the propensity 
to intensify the effect of class-specific resistance, most scientists would prefer to have 
more novel classes with no pre-existing potential cross-resistance.54 
 
Phase 2 Ongoing 
 
 There are currently three agents that are in Phase 2 clinical trials for the treatment 
of gram-negative bacteria.  The first agent is combination agent.  It combines ceftazidime 
and NXL 104 (Figure 1.35).  Ceftazidime is a cephalosporin, and NXL 104 is a new  
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Figure 1.33: Structure of AFN-1252 
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β-lactamase inhibitor.  These agents are used in combination so as to increase the 
cephalosporin’s activity against most β-lactamase producing bacteria.  This would be the 
first resumption of this established approach to protect a β-lactam antibiotic against 
resistance caused by β-lactamases since the approval of piperacillin/tazobactam in 1993.  
This combination has been shown to be stable against class A and class C β-lactamase, 
and is being tested for the treatment of complicated urinary tract infections. 
  
The second agent in Phase 2 clinical trials is IC43.  This is a recombinant subunit 
vaccine consisting of two outer membrane proteins of Pseudomonas aeruginosa.  It is 
being tested for the treatment of ventilator-associated pneumonia.  The final agent that is 
currently undergoing Phase 2 trials is KBPA101.  This agent is a monoclonal antibody 
that targets Pseudomonas aeruginosa serotype O11.  It is also associated with the co-
development of a multivalent diagnostic test for rapid serotyping. 
 
Phase 1 Ongoing 
 
 The first agent that is currently undergoing Phase 1 clinical trials is KB001.  This 
is a humaneered monoclonal antibody fragment.  It is an antivirulence antibody that 
targets PcrV protein of the Type III secretion system of Pseudomonas aeruginosa.  It is 
being tested for the treatment of cystic fibrosis and ventilator-associated pneumonia.  The 
next agent is ACHN-490 (Figure 1.36).  It is an aminoglycoside that is active against 
aminoglycoside-resistant gram-negative pathogens.  The final agent is CB-182804.  It is a 
lipopetide that shows activity against Escherichia coli, Acinetobacter, Pseudomonas 
aeruginosa, and Klebsiella. 
 
Pre-clinical 
 
 There are a number of agents that are either currently in pre-clinical trials or have 
completed pre-clinical trials, but are not in Phase 1 trials.  The first agent that has 
completed the pre-clinical trials is ceftaroline with NXL 104.  This is another 
cephalosporin combined with a new β-lactamase inhibitor.  This agent proves to be stable 
against class A and class C β-lactamases.  It is also shows efficacy against enterobacteria, 
Pseudomonas aeruginosa, and MRSA.  The last agent that has completed clinical trials is 
POL7080.  POL7080 belongs to a novel class of antibiotics called protein epitope 
mimetics.  This agent is specific for Pseudomonas aeruginosa. 
 
 The following agents are all currently involved in pre-clinical trials.  The first is 
CXA-101 (Figure 1.37).  This agent is a cephalosporin and is more stable against class C 
β-lactamases than ceftazidime.  The next agent is BAL 30072 (Figure 1.38).  It is a 
monobactam antibiotic.  It is stable against class C and class B enzymes (metallo-β-
lactamases).   
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Figure 1.36: Structure of ACHN-490 
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Figure 1.37: Structure of CXA-101 
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Figure 1.38: Structure of BAL 30072 
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Concluding Introductory Remarks 
 
 The entire drug discovery process is mediated by the role that medicinal chemists 
play.  Without the knowledge and guidance of medicinal chemists, the agents discussed 
in this chapter would, for the most part, not exist.  Medicinal chemistry plays a pivotal in 
the process for drug development.  Medicinal chemists can begin the discovery process 
by finding a hit compound.  The hit compound can be identified in a number of ways; 
including computationally, through high-throughput screening, or chemical intuition 
developed over numerous years of training and study.  From the hit compound, medicinal 
chemists can then lead that compound through the optimization process.  During the 
optimization process, synthetic medicinal chemists utilize their training and knowledge to 
improve the potency, efficacy, and pharmaceutical profile of the hit compound into a lead 
compound.  This lead compound can then begin evaluation for pre-clinical trials in hopes 
that it will enter clinical trials to become a marketable drug. 
 
 It is clear from the information presented in this chapter that the need to develop 
novel antibiotics is still strong.  There has been a push to develop new agents for the 
treatment of gram-positive bacteria, due to the prevalence of MRSA, and that is now 
reflected in the antibiotic pipeline.  There are several agents in advanced the advanced 
stages of approval for gram-positive infections.  However, the real dilemma is present in 
the realm of gram-negative infections.  There is an ever increasing prevalence of gram-
negative bacterial resistance; this could be related to the push to develop new gram-
positive active agents while gram-negative infections were all but ignored.  As of late, 
there has been a push to develop new gram-negative active agents.  These agents are just 
beginning to filter into the antibacterial pipeline, and therefore have a long ways to go 
before they are available for human use.  The time that is going to elapse between now 
and when these agents become available is going to be pivotal to see how bad the issue of 
gram-negative resistance becomes.  The current antibacterial pipeline does show some 
promise for the future of antibacterial research, but it must people should not become lax.  
This field is always in need of novel research, and should not be neglected. 
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CHAPTER 2: NOVEL UREA DERIVATIVES AS ANTI-TUBERCULOSIS 
AGENTS 
 
 
Introduction to Tuberculosis 
 
 Mycobacterium tuberculosis is the causative agent of human tuberculosis (TB).  
This bacteria was first described in detail by Robert Koch in 1882.55,56  TB primarily 
manifests itself as a respiratory tract infection attacking the lungs, but it can also affect 
the central nervous system, lymphatic system, circulatory system, bones, joints, and even 
the skin.57  The respiratory manifestation of the disease can be easily spread via aerosol 
droplets that result from coughing, sneezing, speaking, or other forms of expulsion from 
the mouth and nose.58  TB is a deadly disease.  It is estimated that one-third of the 
world’s population (two billion people) is infected with the TB bacilli.  Of the two billion 
people infected with the bacilli, approximately eight million will develop active 
tuberculosis and approximately 1.6 million people will die per annum.58-63 
 
 There are two stages of this disease: latent TB and active TB.64,65  In general, 
patients with the latent form of the disease are asymptomatic and not contagious.  The 
opposite is true for patients with the active TB.  Only about 5-10% of individuals with the 
latent form of TB will ever develop active TB.  However, that statistic changes 
dramatically if the patient becomes immunocompromised, such as with human 
immunodeficiency virus (HIV).  In such an instance, the rate increase to 10% per year.66  
While TB is a very deadly disease, treatment options are available. 
 
 
Treating Tuberculosis 
 
 Chemotherapy for TB started in the 1940s.  In 1943, anti-TB research resulted in 
the discovery of active anti-TB agents, and strategies have been subsequently devised to 
treat TB.58,67-70  Chemotherapeutic action is required once a patient develops active TB.  
There are two lines of agents used in the treatment of TB depending upon whether or not 
the bacteria have developed resistance to the first set of agents.  The first-line therapy for 
TB consists of rifampin (RIF), isoniazid (INH), pyrazinamide (PZA), streptomycin (SM), 
and ethambutol (EMB) (Figure 2.1).  The second-line agents, which are reserved for 
cases of resistance, retreatment, or intolerance to first-line drugs, include ethionamide, 
para-aminosalicyclic acid, cycloserine, capreomycin, and kanamycin (Figure 2.2).5  Due 
to the fact that TB has the ability to manifest itself in a latent state, and it is also a slow 
growing bacteria, the treatment time for a regimen of antibiotics is usually between 6-9 
months to effectively rid the body of the bacteria.57  With the current antibiotics, 
regimens shorter than six months are not allowed due to the high rate of relapse.71  The 
reason the second-line agents are not used as first-line is due to the fact that although they 
are active against TB, they are usually not well tolerated having higher incidences of 
adverse side effects, and are less efficacious requiring even longer therapy to rid the body 
of the bacteria.5 
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Isoniazid 
 
 The antibiotic isoniazid (INH) is an orally active synthetic agent that was 
discovered in the mid 1900s to be active against tuberculosis.  However, INH is only 
active against the actively growing form of the bacteria.57  INH exerts its anti-
tuberculosis activity by binding to one of the condensing enzymes (inhA) in the fatty acid 
biosynthesis pathway.72-75  A mutation within this gene was shown to confer resistance to 
INH, thus suggesting that inhA is the target of this drug.76,77  It is a prodrug that must be 
enzymatically activated in the body.  In the case of INH, it is activated by the TB 
catalase-peroxidase enzyme (katG) to the activated radical acyl anion.78,79  This form of 
the drug reacts with nicotinamide adenine dinucleotide (NADH) to form a complex that 
binds tightly to inhA inhibiting the synthesis of mycolic acids in the mycobacterial cell 
wall.72  It has been reported that NAD-adducts have a secondary effect on almost every 
aspect of mycobacterial metabolism.80   
 
Rifampin 
 
 Rifampin is an orally active, highly effective semi-synthetic antibiotic.  It shows 
bactericidal activity against all populations of mycobacteria.  The introduction of 
rifampin to the standard treatment regimen reduced the duration of chemotherapy by half, 
from 18 to 9 months.57  RIF inhibits the β-subunit of RNA polymerase, thus preventing 
the transcription of DNA to RNA and the successive translation of proteins in 
mycobacteria.81  Resistance to RIF develops when a mutation occurs in the gene 
responsible for the β-subunit of the RNA polymerase (rpoB) causing the antibiotic to no 
longer be able to bind RNA polymerase.82   
 
Pyrazinamide 
 
Pyraziamide (PZA) is an orally active synthetic analog of nicotinamide.  It 
exhibits slightly bactericidal activity on actively replicating bacteria, but overall is 
thought to act by a sterilizing effect.58  The activity of PZA is pH dependent.  Good in 
vivo activity is seen at pH 5.5, but it is nearly inactive at neutral pH.5  PZA is also a 
prodrug that must be enzymatically activated by pyrazinamidases to convert it to its 
active from, pyrazinoic acid, which inhibits energy metabolism.83-85  The introduction of 
PZA into the treatment regimen reduced treatment time from 9 months to 6.5,86,87 
 
Ethambutol 
 
Ethambutol (EMB) is synthetic amino alcohol.88-90  Ethambutol is a bacteriostatic 
agent that inhibits arabinogalactan biosynthesis, a primary component of the 
mycobacterial cell wall.91,92  It disrupts the cell wall of the mycobacteria allowing for 
other agents to better penetrate the bacilli and destroy it more effectively.  EMB 
resistnace involves a gene over expression and mutations of arabinosyl transferase which 
is encoded by the embB gene.92,93 
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Streptomycin 
 
 Streptomycin is an aminoglycoside antibiotic.58  It is bacteriostatic, and used in 
the treatment of drug resistant tuberculosis.57  Streptomycin acts by penetrating the inner 
membrane of Mycobacterium tuberculosis and binding to the 30S ribosomal subunit, thus 
inhibiting protein synthesis.94  This agent is associated with many toxic manifestations on 
the peripheral and central nervous system at higher doses, and hypersensitivity reactions, 
therefore it is not a drug of popular choice.58   
 
 
Need for Novel Anti-Tuberculosis Agents 
 
 A number of once active anti-tuberculosis drugs are now inactive due to the ever 
increasing rise in drug resistant strains of tuberculosis.58  This is a frightening statistic in 
itself, but coupled with the fact that there have been no new first-line chemotherapeutic 
agents developed to combat TB in the last 35 years, it becomes staggering.9  While these 
agents may still be effective, there are still problems in treating TB, including poor 
patient compliance which leads to the development of more drug resistant strains.  There 
is a lack in patient compliance due in large part to the fact that the current treatment 
regimen lasts 6-9 months.  The length of the treatment is due to the difficulty in killing 
off the latent and slow-growing bacteria.  Drug-resistant TB is a major public health issue 
in many developing countries around the world.59   
 
The appearance of multi-drug resistant TB (MDR-TB) occurs when drug-
susceptible TB is improperly or incompletely treated.  According to the World Health 
Organization (WHO), MDR-TB is defined as a resistance to the two most effective first-
line TB agents: rifampin and isoniazid.59  When a strain of TB becomes unresponsive to 
any fluoroquinolone and at least one of the three second-line agents (capreomycin, 
kanamycin, and amikacin), it becomes described at extensively drug-resistant TB (XDR-
TB).59  There are several ways in which a person can become infected with drug-resistant 
TB, including not taking the prescribed course of drugs appropriately or becoming 
infected by an individual with a drug-resistant strain.65  As is evident by these facts, there 
is an ever growing need to develop novel agents for the treatment of tuberculosis.  These 
new agents need to be potent, fast-acting, have an excellent 
pharmacokinetic/pharmacodynamic (PK/PD) profile, have a high therapeutic index, and 
preferably have a novel mechanism of action as to avoid cross-resistance with other 
agents. 
 
 
Targeting Epoxide Hydrolase 
 
Increasing drug resistance and poor activity of existing therapies towards the 
latent stage of Mycobacterium tuberculosis infection has produced a clear need to 
develop novel therapeutics to treat tuberculosis.95  Thus fast-acting drugs with novel 
mechanisms of action that are not cross resistant to existing drugs are being sought 
actively.  To tackle this problem two primary screening strategies are being applied in 
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tuberculosis drug discovery-target based high throughput screening and phenotypic 
minimum inhibitory concentration (MIC) based screening of whole cell bacteria.   
 
Although target / enzyme based high throughput screening for new tuberculosis 
therapeutics has been widely adopted, this strategy has not produced many notable 
successes. This experience mirrors the success of other antibacterial drug discovery 
programs.96  On the contrary, phenotypic direct MIC based screening of commercial and 
proprietary libraries has recently produced a number of interesting clinical candidates 
including the diaryl quinolone, TMC207, and benzothiazinone, BTZ043,97,98 for which 
the ultimate enzymatic target and antitubercular mode of action for these compounds was 
derived after potent inhibitors were identified. 
 
We have adopted an analogous phenotypic screening approach to screen various 
available chemical libraries directly for anti-tuberculosis activity and then follow up hits 
that are shown to be selective with mode of action studies to produce novel validated 
anti-tubercular drug candidates.99  This study included the screening of a compound 
library from LeadScreen (Tripos) for anti-tuberculosis activity by microbroth dilution in 
Middlebrook 7H9 media.  This screen identified urea derivative 1, which displayed an 
MIC of 0.3 µM (0.01 µg/ml) (Figure 2.3). Interestingly, the structure of the urea 
compound 1 is very similar to inhibitors of mammalian soluble epoxide hydrolase 
(sEH)100 (Figure 2.4) and the recently reported inhibitors of the tuberculosis epoxide 
hydrolase (EH) enzyme B.101 
 
Initially it was thought that the tuberculosis genome contained six putative EH 
enzymes, but it is now suggested that the M. tuberculosis genome contains at least 30 
members of the EH family.101  Consequently, these enzymes may represent good targets 
for tuberculosis drug discovery as they play essential roles in the detoxification of various 
substances in addition to lipid metabolism.  Since M. tuberculosis contains several EHs, 
which are likely to be redundant, a target driven approach appears inferior to the 
phenotypic MIC for rapidly determining the initial therapeutic potential of EH inhibition.  
Currently, there are no reports on the whole cell anti-tubercular activity of EH inhibitors.  
In this study, the three sections of hit 1 were systematically modified to develop a detail 
anti-tubercular structure activity relationship for this series of compounds that represent 
analogs of EH inhibitors. 
 
 
Chemistry 
 
The optimization of compound 1 began by modifying each side of the urea moiety 
with a selection of substituents to probe the anti-tubercular structure activity relationship.  
These positions are shown as R (aryl) and R΄ (adamantyl).  The synthesis of these 
derivatives was carried out by reacting the desired amine and with an isocyanate in 
dichloromethane in the presence of triethylamine (Scheme 2.1).  Using this facile  
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Figure 2.3: Lead Compound 1 
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Figure 2.4: Inhibitors of Mammalian Soluble Epoxide Hydrolase 
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Scheme 2.1: Synthesis of First Urea Series 
 
 
 
 
 
 
Reagents and Conditions: (a) triethylamine, dry dichloromethane, room temperature, 
overnight. 
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chemistry, an array of compounds (1-30) was rapidly synthesized using parallel synthesis 
all in good yields (>75%).   
 
The second series of compounds was synthesized focusing on modifications of 
the urea moiety (Scheme 2.2A).  The first compound targeted was the thiourea derivative 
31 as there are already known thiourea drugs such as isoxyl and thiocarlide.102,103  As 
shown in Scheme 2.2A, this synthesis was identical to the urea synthesis with the 
exception that the isothiocyanate was used in place of the isocyanate to give 31 in good 
yield.   
 
The synthesis of the carbamate derivative 32 is discussed next.  This synthesis 
coupled the adamantyl alcohol with the phenyl isocyanate in order to form the desired 
product again in high yield (Scheme 2.2B).  Further modification of the urea moiety is 
shown by the synthesis of the mono- and dimethylated derivatives 33 and 34 (Scheme 
2.2C).  The synthesis of the 33 started from 1, which was selectively deprotonated at the 
more acidic urea nitrogen adjacent to the phenyl ring with n-butyl lithium at low 
temperature.  The anion was then reacted with iodomethane to form compound 33 in 
good yield.  Di-N-methylated urea 34 was obtained in an analogous fashion using 
increased equivalents of n-butyl lithium and iodomethane. 
 
The final series of compounds synthesized aimed to decrease the lipophilicity by 
the introduction of oxygen containing substituents, as poor solubility was noted in 
preliminary testing of the first two series of compounds.  The first compound targeted 
was reference compound 36, a known inhibitor of human EH’s which has been shown to 
be orally bioavailable.  36 was synthesized according to the published synthesis of T. 
Kasagami et. al. (Scheme 2.3).104,105 
 
Other oxygenated urea analogs 37-41 were synthesized according to Scheme 2.1.  
To complete the series compound 42, the urea derivate of the tuberculosis drug isoxyl, 
was synthesized (Scheme 2.4).  42 was synthesized by alkylating 4-nitrophenol with 1-
bromo-4-methylpentane to produce the O-alkylated intermediate.  This nitro intermediate 
was then reduced by hydrogenolysis to produce the aniline intermediate.  This compound 
was then reacted with triphosgene or thiophosgene to produce the 42 and 43 (Isoxyl) in 
acceptable yields. 
 
 
Results and Discussion 
 
Overall, the first series of urea compounds showed good activity primarily against 
M. tuberculosis (H37Rv) (Table 2.1).  In this series, compounds 1, 3, 11, 20, 24 showed 
the best activity with an MIC value of 0.01 µg/mL that is comparable to the anti-
tuberculosis drug isoniazid (0.01 µg/mL).  Some significant structure activity 
relationships (SAR) has emerged from this data.  The one substituent has a strong 
preference for the bulky aliphatic ring system such as adamantly.  Substituting adamantyl 
for a cyclohexyl 8 or cyclopentyl 9 considerably decreased the activity, while a 
cyclooctyl 7 ring system only minimally decreased the activity to a level comparable to 
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Scheme 2.2: Synthesis of Variations around Urea Moiety 
 
 
 
Reagents and Conditions: (a) triethylamine, dry dichloromethane, room temperature, 
overnight; (b) triethylamine, dry dichloromethane, room temperature, overnight; (c) (i) n-
BuLi, dry THF, -78˚C; (ii) iodomethane, reflux, 24 hr; (d) (i) n-BuLi, dry THF, -78˚C; 
(ii) iodomethane, reflux, 24 hr. 
 
 
 
 
Scheme 2.3: Synthesis of Compound 36 
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Reagents and Conditions: (a) conc. H2SO4, dry MeOH, reflux, 12 hr; (b) dry 
dichloroethane, reflux, 4 d. 
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Scheme 2.4: Synthesis of Compounds 42 and 43 
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Reagents and Conditions: (a) 1-bromo-4-methylpentane, NaOH, DMF, 65˚C, overnight; 
(b) Pd/C, H2, ethanol, overnight; (c) triphosgene, triethylamine, DCM, room temperature, 
overnight; (d) thiophosgene, triethylamine, DCM, room temperature, overnight.  
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Table 2.1: In Vitro Antibacterial Activity of First Urea Series 
 
No. Structure MIC (µg/mL) 
Cytotox 
(µg/mL) 
     
R 
1 
 
0.01 219 
2 
 
0.4 725.8 
3 
 
0.01 1.18 
4 
 
6 129.7 
5 
 
0.02 16 
6 
 
0.2 15.5 
7 
 
0.8 63.4 
8 12.5 15.9 
9 50 nda 
 
 
  
R 
10 
 
0.4 7.1 
11 
 
0.01 30.2 
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Table 2.1: Continued 
 
No. Structure MIC (µg/mL) 
Cytotox 
(µg/mL) 
12 
 
0.1 9.7 
13 
 
3.125 4.2 
14 
 
1.6 26.4 
15 
 
50 23.4 
16 
 
12.5 371.9 
17 
 
12.5 170.9 
18 
 
10 25 
19 
 
0.39 11.62 
20 
 
0.01 174.8 
21 
 
0.2 20 
 
O
N
H
N
H
R
Cl  
  
R 
22 
 
0.02 4.34 
23 
 
3.3 186.4 
24 
 
0.01 >1000 
25 
 
6 342.3 
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Table 2.1: Continued 
 
No. Structure MIC (µg/mL) 
Cytotox 
(µg/mL) 
 
O
N
H
N
H
R
Cl  
  
R 
26 
 
6 >1000 
 
 
  
R 
27 
 
3 nd 
28 
 
0.8 25.3 
29 
 
1.6 38.5 
30 
 
1.6 193.2 
 
a nd = not determined 
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the drug ethambutol (0.8 µg/mL).  Substitution in the aryl ring at the meta and/or para 
positions (Compounds 10-14) were more tolerated with those substitutions not having a 
major impact on the anti-tuberculosis activity.  In the group of compounds which contain 
the trifluorophenyl moiety (Compounds 1-9), the adamantyl compounds 1 and 3 exhibit 
the best activity with potent MIC values of 0.01 µg/mL.   
 
It can be seen that within this series the bulky hydrophobic adamantyl group is 
preferred over a straight-chain alky group 4 or even a simple cyclic alkyl group 8 and 9 
which lack the bulk of the adamantyl group.  With regard to compounds that only contain 
aliphatic groups (Compounds 15-21), it can be seen that the best MIC value is displayed 
by the most hydrophobic compound with the longest alkyl chain 20.  When comparing 
the compounds with the 3-chloro-4-methylphenyl substitution (Compounds 22-26), it can 
be seen that compound with a bulky alkyl rings on the opposite side (adamantyl and 
cyclooctyl) produce the most active compounds (22 and 24).  This trend continues in the 
compounds in the 2-fluoro-3-(trifluoromethyl)phenyl arylurea series 27-30. 
 
The MIC data for the second series of compounds in which the central urea 
moiety was modified is shown below (Table 2.2).  In this series, it is clearly seen that the 
unmodified urea moiety is preferred for best anti-tuberculosis activity.  Introduction of a 
thiourea 31 produces a decrease in activity.  Replacing the urea with a carbamate 32 
produces a 10-fold larger decrease in potency.  Mono N-methylation of the urea 33 shows 
similar decrease in activity and di-N-methlyation 34 produces an even greater decrease in 
activity.   
 
The MIC data for the third series of oxygenated ureas is shown below (Table 2.3).  
Compounds 35 and 36 showed good antitubercular activity while the remaining 
compounds 37-41 had much poorer activity.  It is of interest to note that 35 and 36 were 
the only two in this series which contained the preferred SAR arrangement of having a 
bulky aliphatic ring on one side of the molecule and having an aromatic ring on the other.  
When comparing compounds 37 and 38 to aliphatic analog 28, it can be seen that placing 
the oxygen in the alkyl chain dramatically decreases antitubercular activity.  Compound 
42, the urea analog of thiourea tuberculosis drug thiocarlide, was found to be inactive.  
This is in contrast to the comparison of compounds 1 and 31, where it was shown that 
replacing the urea moiety with a thiourea decreased the activity but 31 still had some 
antitubercular activity demonstrating the contribution of the adamantyl and phenyl groups 
to the overall activity. It can mean that thiocarlde acts on a different target than the 
compounds selected here. 
 
 
Conclusions 
 
In this study, clear structure activity relationships (SAR) for anti-tubercular 
activity of urea-based EH inhibitors has emerged with the best compounds containing a 
1-cylcoalkyl-3-phenyl disubstituted urea structure. The 1-3 disubstituted urea moiety was 
shown to be most active over other urea substitution patterns and urea bioisosteres. For  
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Table 2.2: In Vitro Antibacterial Activity of Compounds with Varying Urea 
Moieties  
 
 
 
 
No.   
M. tb  
MIC (µg/mL) 
  X Y Z 
1 NH O NH 0.01 
31 NH S NH 0.8 
32 O O NH 6 
33 NH O NMe 6 
34 NMe O NMe 12 
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Table 2.3:  In Vitro Antibacterial Activity of Miscellaneous Urea Compounds 
 
No. Structure 
 
 
MIC 
(µg/mL)
 
 
Cytotox 
(µg/mL) 
 
35 0.4 13.4 
   
R 
36 0.39 30.3 
37 50 nda 
38 100 20.4 
39 25 6.4 
40 O 25 264.8 
41 
O
N N
H
O
F
F
F
O
>100 nd 
42 200 nd 
Thiocarlide
O O
H
N
H
N
S
2.5 nd 
 
a nd = not determined 
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the cycloalkyl ring subsituent, a strong preference for bulkyl groups such as adamantyl 
was preferred for anti-tubercular activity.   
 
This is consistent with previous findings by Biswal et al.,101 which indicates the 
importance of the adamantyl substituent in inhibiting M. tuberculosis EH enzyme B.  
Therefore, bulky groups such as adamantyl appear relevant for both enzyme and whole 
cell activities.  This is noteworthy as other adamantyl analogs have been shown to have 
good anti-tubercular activity; most notably the clinical candidate adamantyl diamine 
SQ109 and admanatyl amides discovered through high throughput screening by the 
National Institutes of Health (NIH) sponsored Tuberculosis Antimicrobial Acquisition 
and Coordinating Facility (TAACF) program.91,106,107  Substitutions to the phenyl ring 
were well tolerated; suggesting further analogs of this position may be worthwhile.  
 
This SAR provides support that α/β-hydrolase fold EHs may be actual targets of 
ureas in M. tb due to structural similarities of these compounds to human sEH inhibitors. 
Evidence for a specific mode of action is bolstered by a lack of correlation between 
lipophilicity and MIC against M. tb, suggesting that activity was not due to membrane 
disruption.  This is further supported by several compounds exhibiting good activity 
against M. smegmatis and the general lack of activity of most analogs against other gram-
positive and –negative bacterial pathogens including Staphylococcus aureus, Bacillus 
anthracis, Esherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae.  Both 
of these affects will be more closely analyzed in upcoming studies.  In general all urea-
based compounds with potent MICs that were comparable to isoniazid and ethambutol 
(0.01-1.6 µg/mL), showed good therapeutic selectivity for M. tuberculosis with 
selectivity indices of 16.5->21,900.   Importantly, this indicates that selective inhibitors 
of the mycobacterial EHs may be obtained.  Increasing solubility, metabolic stability and 
selectivity away from inhibition of human EHs are currently the principal design drivers 
that are being used to further optimize this series. 
 
 Currently, computer-based structure docking experiments are being conducted my 
members of Dr. Richard Lee’s laboratory.  These findings will be used to further guide 
the future directions of this project.  Initial studies are being performed in an effort to 
establish a model which can effectively predict that activity of potential inhibitors before 
they are synthesized in the laboratory.  This computer model provides details of how the 
inhibitors bind into the active site of the epoxide hydrolase enzyme found in 
Mycobacterium tuberculosis (Figure 2.5).  This figure depicts the modeled interactions of 
compound 1 (ball and stick form with yellow carbons) within the active site of 
Mycobacterium tuberculosis epoxide hydrolase B (EphB) with the catalytic residues 
(tube form with grey carbons).  Panel A shows the 90o left side view of the hydrophobic 
pocket where the adamantyl functionality resides.  Panel B shows the front view of the 
hydrogen bonding network with the catalytic residues Tyrosine 164, Tyrosine 272, and 
Aspartic Acid 104 to the urea moiety of compound 1.  Panel C displays the 90o right side 
view and key interactions of the aromatic binding pocket. 
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Figure 2.5:      Hydrogen Bonding Network 
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Experimental Section 
 
 
Chemistry 
 
All anhydrous solvents and starting materials were purchased from Aldrich 
Chemical Co. (Milwaukee, WI).  All reagent grade solvents used from chromatography 
were purchased from Fisher Scientific (Suwanee, GA) and flash column chromatography 
silica cartridges were obtained from Biotage Inc. (Lake Forest, VA).  The reactions were 
monitored by thin-layer chromatography (TLC) on pre-coated Merch 60 F254 silica gel 
plates and visualized using ultraviolet (UV) light (254 nm).  A Biotage FLASH column 
chromatography system was used to purify mixtures.  All 1H nuclear magnetic resonance 
(NMR) spectra were recorded on a Varian INOVA-500 spectrometer.  Chemical shifts (δ) 
are reported in parts per million relative to the residual solvent peak or internal standard 
(tetramethylsilane), and coupling constants (J) are reported in hertz (Hz).  Mass spectra 
were recorded on a Bruker Esquire liquid-chromatography mass-spectrometer using 
electrospray ionization.  Purity of the products was confirmed before testing by analytical 
reverse phase-high performace liquid chromatography on a Shimadzu high-performance 
liquid-chromatography system, and all final compounds had a purity of 95% or greater as 
determined by RP-HPLC. Gradient Conditions: solvent A (0.1% Trifluoroacetic Acid 
(TFA) in water) and solvent B (acetonitrile): 0-2.00 min 100& A, 2.00-7.00 min 0-100% 
B (linear gradient), 7.00-8.00 min 100% B, UV detection at 254 nm.  Melting points were 
obtained on the OptiMelt MPA100 Automated Melting Point System. 
 
 
General Method for the Synthesis of Urea Compounds 
 
In a round bottom flask equipped with a stir bar, 1.2 mmol of the appropriate 
amine was added to 10 mL of anhydrous dichloromethane. To this solution, 1.0 mmol of 
the appropriate isocyanate followed by 3.6 mmol of triethylamine was added. The 
reaction was stirred at room temperature overnight. The solvent was removed by rotary 
evaporation. The resulting residue was purified by flash chromatography using a 
petroleum ether to ethyl acetate gradient to elute the final compound. 
 
1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)urea (1). 1H NMR (DMSO-d6): δ 1.58 (2H, 
d, J = 12 Hz), 1.80 (12H, m), 3.78 (1H, d, J = 8.0 Hz), 6.96 (1H, d, J = 8.0 Hz), 7.20 (1H, 
q), 7.96 (1H, m), 8.51 (1H, s).  RP-HPLC: tR = 7.18 min. ESI-MS m/z:  347.1 [M + Na]+. 
Mp: 229-230 °C. 
 
1-(1-adamantyl)-3-(2,3,4-trifluorophenyl)urea (2). 1H NMR (DMSO-d6): δ 1.63 (6H, 
s), 1.93 (6H, s), 2.03 (3H, s), 6.44 (1H, s), 7.16 (1H, q, J = 10.0 Hz), 7.88 (1H, m), 8.26 
(1H, s). RP-HPLC: tR = 7.29 min. ESI-MS m/z: 347.1 [M + Na]+. Mp: 216-219 °C. 
 
1-(1-(1-adamantyl)methyl)-3-(2,3,4-trifluorophenyl)urea (3). 1H NMR (DMSO-d6): δ 
1.55 (12H, m), 1.94 (3H, m), 2.81 (2H, d, J = 6.0 Hz), 6.60 (1H, t, J = 5.5 Hz), 7.19 (1H, 
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q, J = 9.5 Hz), 7.92 (1H, m), 8.44 (1H, s). RP-HPLC: tR = 7.08 min. ESI-MS m/z: 361.3 
[M + Na]+. Mp: 171-173 °C. 
 
1-heptyl-3-(2,3,4-trifluorophenyl)urea (4). 1H NMR (DMSO-d6): δ 0.87 (3H, t, J = 6.5 
Hz), 1.24 (8H, s), 1.42 (2H, m), 3.08 (2H, q, J = 6.5 Hz), 6.57 (1H, t, J = 5.0 Hz), 7.19 
(1H, q, J = 9.0 Hz), 7.84 (1H, m), 8.40 (1H, s). RP-HPLC: tR = 7.04 min. ESI-MS m/z: 
311.1 [M + Na]+. Mp: 96-98 °C. 
 
1-(2,3,4-trifluorophenyl)-3-(2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)urea (5). 1H 
NMR (DMSO-d6): δ 0.90 (1H, d, J = 9.5 Hz), 1.00 (3H, s), 1.06 (3H, d, J = 7.0 Hz), 1.20 
(3H, s), 1.52 (1H, m), 1.79 (2H, m), 1.91 (1H, m), 2.44 (2H, m), 3.97 (1H, quintuplet, J = 
8.0 Hz), 6.70 (1H, d, J = 8.0 Hz), 7.18 (1H, q, J = 9.5 Hz), 7.88 (1H, m), 8.26 (1H, s). 
RP-HPLC: tR = 7.26 min. ESI-MS m/z: 349.1 [M + Na]+. Mp: 156-159 °C. 
 
1-((6,6-dimethylbicyclo[3.1.1]heptan-2-yl)methyl)-3-(2,3,4-trifluorophenyl)urea (6). 
1H NMR (DMSO-d6): δ 0.86 (1H, d, J = 9.5 Hz), 1.00 (3H, s), 1.17 (3H, s), 1.44 (1H, m), 
1.86 (5H, m), 2.10 (1H, m), 2.33 (1H, m), 3.08 (2H, m), 6.62 (1H, t, J = 5.5 Hz), 7.17 
(1H, q, J = 10.0 Hz), 7.86 (1H, m), 8.38 (1H, s). RP-HPLC: tR = 7.30 min. ESI-MS m/z: 
349.1 [M + Na]+. Mp: 105-107 °C. 
 
1-cyclooctyl-3-(2,3,4-trifluorophenyl)urea (7). 1H NMR (DMSO-d6): δ 1.55 (13H, m), 
1.76 (2H, t, J = 9.5 Hz), 6.63 (1H, d, J = 8.0 Hz), 7.18 (1H, q, J = 9.5 Hz), 7.89 (1H, m), 
8.31 (1H, s). RP-HPLC: tR = 6.98 min. ESI-MS m/z: 323.1 [M + Na]+. Mp: 160-163 °C. 
 
1-cyclohexyl-3-(2,3,4-trifluorophenyl)urea (8). 1H NMR (DMSO-d6): δ 1.19 (3H, m), 
1.32 (2H, m), 1.53 (1H, m), 1.65 (2H, m), 1.80 (2H, m), 3.48 (3H, m), 6.60 (1H, d, J = 
9.0 Hz), 7.20 (1H, q, J = 10 Hz), 7.90 (1H, m), 8.33 (1H, s).  RP-HPLC: tR = 6.39 min. 
ESI-MS m/z: 295.0 [M + Na]+. Mp: 188-191 °C. 
 
1-cyclopentyl-3-(2,3,4-trifluorophenyl)urea (9). 1H NMR (DMSO-d6): δ 1.37 (2H, m), 
1.59 (4H, m), 1.84 (2H, m), 3.94 (1H, q, J = 6.5 Hz), 6.66 (1H, d, J = 7.5 Hz), 7.19 (1H, 
q, J = 9.5 Hz), 7.90 (1H, m), 8.27 (1H, s).  RP-HPLC: tR = 6.14 min. ESI-MS m/z: 281.0 
[M + Na]+. Mp: 184-186 °C. 
 
1-(2-adamantyl)-3-(4-cyanophenyl)urea (10). 1H NMR (DMSO-d6): δ 1.58 (2H, d, J = 
12.0 Hz), 1.79 (12H, m), 3.78 (1H, d, J = 7.5 Hz), 6.67 (1H, d, J = 7.5 Hz), 7.55 (2H, d, J 
= 8.5 Hz), 7.67 (2H, d, J = 8.5 Hz), 8.92 (1H, s). RP-HPLC: tR = 6.83 min. ESI-MS m/z: 
296.1 [M + H]+. Mp: 217-219 °C. 
 
1-(2-adamantyl)-3-phenethylurea (11). 1H NMR (DMSO-d6): δ 1.66 (14H, m), 2.68 
(2H, t, J = 7.0 Hz), 3.24 (2H, q, J = 7.0 Hz), 3.67 (1 H, d, J = 8.0 Hz), 5.82 (1H, t, J = 5.5 
Hz), 6.11 (1H, d, J = 8.5 Hz), 7.21 (3H, d, J = 6.0 Hz), 7.30 (2H, t, J = 7.5 Hz). RP-
HPLC: tR = 6.82 min. ESI-MS m/z: 299.2 [M + H]+. Mp: 115-117 °C. 
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1-(3-acetylphenyl)-3-(2-adamantyl)urea (12). 1H NMR (DMSO-d6): δ 1.57 (2H, d, J = 
12.0 Hz), 1.80 (13H, m), 2.55 (3H, s), 3.79 (1H, d, J = 7.5 Hz), 6.50 (1H, d, J = 7.5 Hz), 
7.38 (1H, t, J = 8.0 Hz), 7.50 (1H, d, J = 8.0 Hz), 7.58 (1H, d, J = 8.0 Hz), 8.00 (1H, s). 
RP-HPLC: tR = 6.63 min. ESI-MS m/z: 335.2 [M + Na]+. Mp: 213-215 °C. 
 
1-(2-adamantyl)-3-benzylurea (13). 1H NMR (DMSO-d6): δ 1.52 (2H, d, J = 12.5 Hz), 
1.78 (12H, m), 3.70 (1H, d, J = 8.0 Hz), 4.21 (2H, d, J = 6.0 Hz), 6.18 (1H, d, J = 8.0 
Hz), 6.27 (1H, t, J = 6.0 Hz), 7.24 (3H, q, J = 7.5 Hz), 7.33 (2H, t, J = 7.5 Hz). RP-
HPLC: tR = 6.37 min. ESI-MS m/z: 285.2 [M + H]+. Mp:  205-207 °C. 
 
1-(2-adamantyl)-3-(3-chloro-2-methylphenyl)urea (14). 1H NMR (DMSO-d6): δ 1.58 
(2H, d, J = 12.5 Hz), 1.77 (10H, m), 1.91 (2H, d, J = 12.5 Hz), 2.26 (3H, s), 3.79 (1H, d, 
J = 7.5 Hz), 6.91 (1H, d, J = 8.0 Hz), 7.03 (1H, d, J = 7.5 Hz), 7.10 (1H, t, J = 8.0 Hz), 
7.87 (2H, m). RP-HPLC: tR = 6.98 min. ESI-MS m/z: 341.1 [M + Na]+. Mp: 254-257 °C. 
 
1-(2-adamantyl)-3-isopropylurea (15). 1H NMR (DMSO-d6): δ 1.02 (6H, d, J = 6.5 
Hz), 1.50 (2H, d, J = 12.5 Hz), 1.75 (12H, m), 3.64 (2H, m), 5.66 (1H, d, J = 7.5 Hz), 
5.95 (1H, d, J = 8.0 Hz). ESI-MS m/z: 237.1 [M + H]+. Mp: 240-242 °C. 
 
1-(2-adamantyl)-3-tert-butylurea (16). 1H NMR (DMSO-d6): δ 1.22 (9H, s), 1.50 (2H, 
d, J = 12.0 Hz), 1.75 (12H, m), 3.64 (1H, d, J = 8.0 Hz), 5.70 (1H, s), 5.95 (1H, d, J = 8.5 
Hz). ESI-MS m/z: 273.1 [M + Na]+. Mp: >300 °C. 
 
1-(2-adamantyl)-3-propylurea (17). 1H NMR (DMSO-d6): δ 0.84 (3H, t, J = 7.0 Hz), 
1.37 (2H, sextuplet, J = 7.5 Hz), 1.51 (2H, d, J = 12.5 Hz), 1.76 (12H, m), 2.94 (2H, q, J 
= 7.0 Hz), 3.66 (1H, d, J = 8.0 Hz), 5.81 (1H, t, J = 5.5 Hz), 6.02 (1H, d, J = 8.0 Hz). 
ESI-MS m/z: 237.1 [M + H]+. Mp: 194-196 °C. 
 
1-(2-adamantyl)-3-cyclohexylurea (18). 1H NMR (DMSO-d6): δ 1.17 (5H, m), 1.51 
(3H, d, J = 12.0 Hz), 1.72 (17H, m), 3.65 (1H, d, J = 7.5 Hz), 5.75 (1H, d, J = 8.0 Hz), 
5.98 (1H, d, J = 8.5 Hz). ESI-MS m/z: 299.3 [M + Na]+. Mp: >300 °C. 
 
1-(2-adamantyl)-3-pentylurea (19). 1H NMR (CDCl3): δ 0.93 (3H, t, J = 6.5 Hz), 1.35 
(4H, m), 1.53 (2H, quintet, J = 7.5 Hz), 1.62 (2H, s), 1.76 (2H, s), 1.80 (1H, s), 1.86 (7H, 
t, J = 11.0 Hz), 1.93 (2H, s), 3.19 (2H, q, J = 7.0 Hz), 3.81 (1H, s), 4.26 (1H, s), 4.64 (1H, 
s).  ESI-MS m/z: 287.1 [M + Na]+. Mp: 151-153 °C. 
 
1-(2-adamantyl)-3-hexylurea (20). 1H NMR (DMSO-d6): δ 0.87 (3H, t, J = 6.5 Hz), 
1.31 (8H, m), 1.50 (2H, d, J = 12.5 Hz), 1.76 (12H, m), 2.97 (2H, q, J = 6.5 Hz), 3.65 
(1H, d, J = 8.0 Hz), 5.78 (1H, t, J = 5.5 Hz), 6.01 (1H, d, J = 8.5 Hz). ESI-MS m/z: 279.3 
[M + H]+. Mp: 95-98 °C. 
 
1-(2-adamantyl)-3-heptylurea (21). 1H NMR (CDCl3): δ 0.90 (3H, t, J = 6.0 Hz), 1.31 
(8H, m), 1.52 (2H, t, J = 6.5 Hz), 1.66 (2H, m), 1.75 (2H, s), 1.77 (1H, s), 1.86 (7H, t, J = 
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11.0 Hz), 1.93 (2H, s), 3.18 (2H, q, J = 6.5 Hz), 3.81 (1H, s), 4.34 (1H, s), 4.70 (1H, s).  
ESI-MS m/z: 315.1 [M + Na]+. Mp: 83-86 °C. 
 
1-(1-(1-adamantyl)methyl)-3-(3-chloro-4-methylphenyl)urea (22). 1H NMR (DMSO-
d6): δ 1.45 (5H, s), 1.64 (7H, m), 1.95 (3H, s), 2.23 (3H, s), 2.79 (2H, d, J = 6.0 Hz), 6.14 
(1H, m), 7.06 (1H, m), 7.17 (1H, d, J = 8.0 Hz), 7.66 (1H, m), 8.46 (1H, s). RP-HPLC: tR 
= 7.24 min. ESI-MS m/z: 355.3 [M + Na]+. Mp: 183-185 °C. 
 
1-(3-chloro-4-methylphenyl)-3-heptylurea (23). 1H NMR (CD3OD): δ 0.93 (3H, m), 
1.35 (8H, m), 1.54 (2H, m), 2.30 (3H, s), 3.19 (2H, t, J = 6.5 Hz), 7.13 (2H, m), 7.53 (1H, 
s). RP-HPLC: tR = 6.99 min. ESI-MS m/z: 305.1 [M + Na]+. Mp: 99-101 °C. 
 
1-(3-chloro-4-methylphenyl)-3-(3-fluorobenzyl)urea (24). 1H NMR (CD3OD): δ 2.30 
(3H, s), 4.40 (2H, s), 7.00 (1H, t, J = 8.5 Hz), 7.08 (1H, d, J = 10.0 Hz), 7.15 (3H, m), 
7.35 (1H, q, J = 6.5 Hz), 7.54 (1H, s). RP-HPLC: tR = 6.38 min. ESI-MS m/z: 315.1 [M + 
Na]+. Mp: 146-148 °C. 
 
1-(3-chloro-4-methylphenyl)-3-cyclooctylurea (25). 1H NMR (DMSO-d6): δ 1.63 (14H, 
m), 2.23 (3H, s), 3.68 (1H, m), 6.13 (1H, d, J = 8.0 Hz), 7.05 (1H, d, J = 8.0 Hz), 7.16 
(1H, d, J = 8.0 Hz), 7.65 (1H, s), 8.35 (1H, s). RP-HPLC: tR =  6.90 min. ESI-MS m/z: 
317.2 [M + Na]+. Mp: 179-182 °C. 
 
1-(3-chloro-4-methylphenyl)-3-(4-phenylbutan-2-yl)urea (26). 1H NMR (CD3OD): δ 
1.20 (3H, d, J = 6.5 Hz), 1.77 (2H, q, J = 7.0 Hz), 2.29 (3H, s), 2.69 (2H, m), 3.82 (1H, 
m), 7.19 (7H, m), 7.54 (1H, s). RP-HPLC: tR = 6.75 min. ESI-MS m/z: 339.1 [M + Na]+. 
Mp: 111-113 °C. 
 
1-(2-fluoro-3-(trifluoromethyl)phenyl)-3-heptylurea (27). 1H NMR (DMSO-d6): δ 
0.86 (3H, t, J = 6.5 Hz), 1.27 (8H, m), 1.43 (2H, t, J = 6.5 Hz), 3.10 (2H, q, J = 6.5 Hz), 
6.67 (1H, t, J = 5.5 Hz), 7.28 (2H, m), 8.42 (1H, t, J = 7.0 Hz), 8.55 (1H, s). RP-HPLC: tR 
= 7.39 min. ESI-MS m/z: 343.1 [M + Na]+. Mp: 77-79 °C. 
 
1-cyclooctyl-3-(2-fluoro-3-(trifluoromethyl)phenyl)urea (28). 1H NMR (CDCl3): δ 
1.67 (14H, m), 1.90 (2H, m), 3.86 (1H, m), 7.25 (2H, d), 8.36 (1H, m). RP-HPLC: tR = 
7.32 min. ESI-MS m/z: 355.1 [M + Na]+. Mp: 127-129 °C. 
 
1-(2-fluoro-3-(trifluoromethyl)phenyl)-3-(4-phenylbutan-2-yl)urea (29). 1H NMR 
(DMSO-d6): δ 1.13 (3H, d, J = 6.5 Hz), 1.71 (2H, d, J = 7.0 Hz), 2.62 (2H, d, J = 7.5 Hz), 
3.70 (1H, m), 6.68 (1H, d, J = 7.0 Hz), 7.22 (7H, m), 8.47 (2H, m). RP-HPLC: tR = 7.12 
min. ESI-MS m/z: 377.0 [M + Na]+. Mp: 145-148 °C. 
 
1-(3-chlorobenzyl)-3-(2-fluoro-3-(trifluoromethyl)phenyl)urea (30). 1H NMR 
(DMSO-d6): δ 4.35 (2H, d, J = 6.0 Hz), 7.22 (1H, t, J = 5.5 Hz), 7.32 (4H, m), 7.39 (2H, 
m), 8.43 (1H, m), 8.76 (1H, s). RP-HPLC: tR = 6.87 min. ESI-MS m/z: 369.0 [M + Na]+. 
Mp:  152-153°C. 
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1-(2-adamantyl)-3-(2,3,4-trifluorophenyl)thiourea (31). In a round bottom flask 
equipped with a stir bar, 2-adamantanamine (0.238 g, 1.27 mmol) was dissolved in 10 
mL of anhydrous dichloromethane. To this solution, 2,3,4-trifluorophenyl isothiocyanate 
(0.14 mL, 1.06 mmol) followed by triethylamine (0.53 mL, 3.80 mmol) was added. The 
reaction was stirred at room temperature overnight. The solvent was removed by rotary 
evaporation. The resulting residue was purified by flash chromatography using a 
petroleum ether to ethyl acetate gradient to elute the final compound (0.330 g, 92%).  1H 
NMR (DMSO-d6): δ 1.62 (2H, d, J = 12.0 Hz), 1.81 (10H, m), 2.01 (2H, s), 4.33 (1H, s), 
7.27 (1H, q, J = 9.5 Hz), 7.66 (1H, s), 8.19 (1H, s), 9.30 (1H, s).  RP-HPLC: tR = 7.10 
min. ESI-MS m/z: 363.1 [M + Na]+. Mp: 176-179 °C. 
 
2-adamantyl 2,3,4-trifluorophenylcarbamate (32). In a round bottom flask equipped 
with a stir bar, 2-adamantanol (0.422 g, 2.77 mmol) was dissolved in 10 mL of anhydrous 
dichloromethane. To this solution, 2,3,4-trifluorophenyl isocyanate (2.79 mL, 2.31 mmol) 
followed by triethylamine (1.15 mL, 8.32 mmol) was added. The reaction was stirred at 
room temperature overnight. The solvent was removed by rotary evaporation. The 
resulting residue was purified by flash chromatography using a petroleum ether to ethyl 
acetate gradient to elute the final compound (0.727 g, 97%).  1H NMR (DMSO-d6): δ 
1.54 (2H, d, J = 11.7 Hz), 1.78 (10H, m), 2.00 (1H, s), 4.78 (1H, s), 7.28 (1H, q, J = 9.6 
Hz), 7.45 (1H, m), 9.46 (1H, s).  RP-HPLC: tR = 7.40 min. ESI-MS m/z: 348.1 [M + Na]+. 
Mp: 114-116 °C. 
 
1-(2-adamantyl)-3-methyl-3-(2,3,4-trifluorophenyl)urea (33).  To a round bottom flask 
containing 1 (0.20 g, 0.617 mmol), anhydrous THF (10 mL) was added under argon.  The 
solution was then cooled to -78°C.  To the cold solution, n-butyl lithium (0.385 mL, 
0.617 mmol) was added drop wise and allowed to stir at -78°C for 10 min.  To this 
solution, iodomethane (0.038 mL, 0.617 mmol) was added drop wise at -78°C.  The 
solution was then allowed to warm to room temperature and then refluxed for 24 hrs.  
The solvent was then removed by rotary evaporation.  The resulting residue was purified 
by flash chromatography using a petroleum ether to ethyl acetate gradient to elute the 
final compound as an oil (0.192 g, 92%).  1H NMR (DMSO-d6): δ 1.45 (2H, d, J = 12.0 
Hz), 1.73 (10H, m), 1.86 (2H, s), 3.14 (3H, s), 370 (1H, s), 5.62 (1H, d, J = 5.5 Hz), 7.26 
(1H, m), 7.34 (1H, q, J = 9.0 Hz).  RP-HPLC: tR = 7.10 min. ESI-MS m/z: 361.2 [M + 
Na]+.   
 
1-(2-adamantyl)-1,3-dimethyl-3-(2,3,4-trifluorophenyl)urea (34).  To a round bottom 
flask containing 1 (0.40 g, 1.23 mmol), anhydrous THF (25 mL) was added under argon.  
The solution was then cooled to -78°C.  To the cold solution, n-butyl lithium (1.54 mL, 
2.47 mmol) was added drop wise and allowed to stir at -78°C for 10 min.  To this 
solution, iodomethane (0.154 mL, 2.47 mmol) was added drop wise at -78°C.  The 
solution was then allowed to warm to room temperature and then refluxed for 24 hrs.  
The solvent was then removed by rotary evaporation.  The resulting residue was purified 
by flash chromatography using a petroleum ether to ethyl acetate gradient to elute the 
final compound (0.190 g, 44%).  1H NMR (DMSO-d6): δ 1.51 (2H, d, J = 12.5 Hz), 1.74 
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(10 H, m), 2.18 (2H, s), 2.66 (3H, s), 3.11 (3H, s), 3.61 (1H, s), 7.23 (1H, m), 7.38 (1H, q, 
J = 9.5 Hz).  RP-HPLC: tR = 7.42 min. ESI-MS m/z: 375.1 [M + Na]+. Mp: 71-74 °C. 
 
1-(2-adamantyl)-3-(4-methoxyphenyl)urea (35). 1H NMR (DMSO-d6): δ 1.57 (2H, d, J 
= 12.5 Hz), 1.79 (12H, m), 3.70 (3H, s), 3.76 (1H, d, J = 8.0 Hz), 6.34 (1H, d, J = 8.0 
Hz), 6.82 (2H, d, J = 8.5 Hz), 7.28 (2H, d, J = 9.0 Hz), 8.20 (1H, s). RP-HPLC: tR = 6.62 
min. ESI-MS m/z: 301.2 [M + H]+. Mp:  125-128 °C. 
 
Methyl 4-(3-(1-adamantyl)ureido)-2-hydroxybenzoate (36). In a round bottom flask 
equipped with a stir bar, 4-amino-2-hydroxy benzoic acid (5.0 g, 32.67 mmol) was 
dissolved in 50 mL of anhydrous methanol.  To this solution concentrated sulfuric acid (7 
mL) was added.  This solution was allowed to reflux overnight.  The solution was 
allowed to cool to room temperature and then sodium bicarbonate was stirred with the 
solution until gas evolution ceased.  The sodium bicarbonate was then filtered off and the 
solution concentrated by rotary evaporation.  The methyl ester was purified by flash 
chromatography using a hexane to ethyl acetate gradient to elute the purified product (3.0 
g, 55%).  The methyl ester (1.204 g, 7.2 mmol) was then taken back up in anhydrous 
dichloroethane (10 mL) and 1-adamantyl isocyanate (1.064 g, 6.0 mmol) added.  The 
solution was refluxed for 4 days.  Pure Lee 1392 (0.85 g, 41%) was obtained by using 
flash chromatography with a hexane to ethyl acetate gradient.  1H NMR (CDCl3): δ 1.68 
(6H, s), 2.05 (9H, m), 3.90 (3H, s), 4.73 (1H, s), 6.62 (1H, s), 6.83 (1H, s), 6.98 (1H, d, J 
= 9 Hz), 7.70 (1H, d, J = 8.5 Hz), 10.83 (1H, s).  RP-HPLC: tR = 6.82 min. ESI-MS m/z: 
367.1 [M + Na]+. Mp: 207-210 °C. 
 
1-(1-adamantyl)-3-(2-ethoxyethyl)urea (37). 1H NMR (CDCl3): δ 1.23 (3H, t, J = 7.0 
Hz), 1.69 (6H, s), 1.98 (6H, s), 2.09 (3H, s), 3.33 (2H, q, J = 5.0 Hz), 3.52 (4H, m), 4.41 
(1H, s), 4.56 (1H, s).  ESI-MS m/z: 289.1 [M + Na]+. Mp: 116-118 °C. 
 
1-(1-adamantyl)-3-(3-methoxypropyl)urea (38). 1H NMR (CDCl3): δ 1.69 (6H, s), 1.77 
(2H, quintet, J = 6.0 Hz), 1.98 (6H, s), 2.09 (3H, s), 3.25 (2H, q, J = 6.0 Hz), 3.36 (3H, s), 
3.49 (2H, t, J = 5.5 Hz).  ESI-MS m/z: 289.3 [M + Na]+. Mp: 135-137 °C. 
 
1-(1-adamantyl)-3-(2-isopropoxyethyl)urea (39). 1H NMR (CDCl3): δ 1.18 (6H, d, J = 
6.0 Hz), 1.68 (6H, s), 1.98 (6H, s), 2.08 (3H, s), 3.30 (2H, q, J = 5.5 Hz), 3.50 (2H, t, J = 
5 Hz), 3.61 (1H, m), 4.50 (1H, s), 4.61 (1H, s).  ESI-MS m/z: 281.5 [M + H]+. Mp: 92-95 
°C. 
 
1-(1-adamantyl)-3-(2-propoxyethyl)urea (40). 1H NMR (CDCl3): δ 0.95 (3H, t, J = 7.5 
Hz), 1.62 (2H, m), 1.69 (6H, s), 1.98 (6H, s), 2.09 (3H, s), 3.33 (2H, q, J = 5.0 Hz), 3.42 
(2H, t, J = 6.5 Hz), 3.50 (2H, t, J = 5.0 Hz), 4.39 (1H, s), 4.54 (1H, s).  ESI-MS m/z: 
303.1 [M + Na]+. Mp: 87-90 °C. 
 
1,1-bis(tetrahydro-2H-pyran-4-yl)-3-(2,3,4-trifluorophenyl)urea (41). 1H NMR 
(CDCl3): δ 1.69 (4H, d, J = 10.5 Hz), 2.17 (4H, m), 3.50 (4H, t, J = 11 Hz), 3.89 (2H, m), 
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4.10 (4H, m), 6.45 (1H, s), 6.96 (1H, q, J = 9.5 Hz), 7.78 (1H, m).  RP-HPLC: tR = 5.58 
min.  ESI-MS m/z: 359.3 [M + H]+. Mp: 191-193 °C. 
 
1,3-bis(4-(isopentyloxy)phenyl)urea (42). To a round-bottom flask, 4-nitrophenol (2.0 
g, 14.37 mmol) and sodium hydroxide (1.73 g, 43.13 mmol), was dissolved in N,N-
dimethylformamide (50 mL).  The solution was stirred at room temperature for 15 min.  
After stirring, 1-bromo-4-methylpentane (5.39 mL, 43.43 mmol) was added to the 
solution and refluxed for 3 h.  The resulting solution was washed with 0.7 N HCl (3  20 
mL) then extracted with diethyl ether (3  20 mL).  The combined organic fractions were 
then washed with brine (3  20 mL) and dried over magnesium sulfate.  The solution was 
then filtered and the solvent by using rotary evaporation.  The crude mixture was then 
purified by flash chromatography using a petroleum ether to ethyl acetate gradient to 
obtain pure intermediate (2.69 g, 90%).  The intermediate nitro compound was then 
converted to an aniline by hydrogenation using Pd/C catalyst overnight.  The aniline was 
used in the next step without further purification (1.85 g, 80%).  In a round bottom flask, 
the aniline (1.27 g, 7.08 mmol) was dissolved in dichloromethane and then triethylamine 
(1.97 mL, 14.16 mmol) was added and the solution was allowed to stir at room 
temperature for 15 min.  In a separate round bottom flask, triphosgene (0.70 g, 2.36 
mmol) was dissolved in dichloromethane.  Then the solution of the aniline was slowly 
added into the solution of thiophosgene under argon and allowed to stir overnight at room 
temperature.  The product (0.301 g, 33%) crashed out of solution and was filtered off and 
washed with dichloromethane.  1H NMR (DMSO-d6): δ 0.93 (12H, d, J = 6.5 Hz), 1.59 
(4H, q, J = 6.5 Hz), 1.77 (2H, m), 3.94 (4H, t, J = 6.5 Hz), 6.85 (4H, d, J = 9.0 Hz), 7.31 
(4H, d, J = 9.0 Hz), 8.35 (2H, s). RP-HPLC: tR = 7.44 min. ESI-MS m/z: 407.3 [M + 
Na]+. Mp: 173-175 °C. 
 
1,3-bis(4-(isopentyloxy)phenyl)thiourea (43). To a round-bottom flask, 4-nitrophenol 
(2.0 g, 14.37 mmol) and sodium hydroxide (1.73 g, 43.13 mmol), was dissolved in N,N-
dimethylformamide (50 mL).  The solution was stirred at room temperature for 15 min.  
After stirring, 1-bromo-4-methylpentane (5.39 mL, 43.43 mmol) was added to the 
solution and refluxed for 3 h.  The resulting solution was washed with 0.7 N HCl (3  20 
mL) then extracted with diethyl ether (3  20 mL).  The combined organic fractions were 
then washed with brine (3  20 mL) and dried over magnesium sulfate.  The solution was 
then filtered and the solvent by using rotary evaporation.  The crude mixture was then 
purified by flash chromatography using a petroleum ether to ethyl acetate gradient to 
obtain pure intermediate (2.69 g, 90%).  The intermediate nitro compound was then 
converted to an aniline by hydrogenation using Pd/C catalyst overnight.  The aniline was 
used in the next step without further purification (1.85 g, 80%).  In a round bottom flask, 
the aniline (1.85 g, 10.9 mmol) was dissolved in dichloromethane and then triethylamine 
(2.88 mL, 20.64 mmol) was added and the solution was allowed to stir at room 
temperature for 15 min.  In a separate round bottom flask, thiophosgene (0.26 mL, 3.44 
mmol) was dissolved in dichloromethane.  Then the solution of the aniline was slowly 
added into the solution of thiophosgene under argon and allowed to stir overnight at room 
temperature.  The product (0.683 g, 50%) crashed out of solution and was filtered off and 
washed with dichloromethane.  1H NMR (DMSO-d6): δ 0.94 (12H, d, J = 7.0 Hz), 1.61 
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(4H, q, J = 7.0 Hz), 1.79 (2H, m), 3.98 (4H, t, J = 7.0 Hz), 6.90 (4H, d, J = 9.0 Hz), 7.10 
(4H, d, J = 9.0 Hz), 9.45 (2H, s).  RP-HPLC: tR = 7.39 min. ESI-MS m/z: 423.2 [M + 
Na]+. Mp: 139-141 °C. 
 
 
MIC Determination 
 
MIC values were determined against M. tuberculosis (H37Rv) and other bacteria 
by the microbroth dilution method.108,109 A broth culture of M. tuberculosis or M. 
smegmatis mc2155 was grown in Middlebrook 7H9 medium with 10% ADC supplement 
to an OD600 of 0.4–0.6. The culture was diluted with 7H9 medium to an OD600 of 0.01, 
and 100µL was added to a microtiter plate containing two-fold serial dilutions of the 
tested compounds for a final volume of 200µL. The plates were incubated at 37 C for 7 
days. The MIC90 was determined by visual inspection and defined as the concentration 
that inhibited 90% of growth.  MICs against other bacteria were performed according to 
the CLSI method and also read by visual inspection.110,111 
 
 
Cytotoxicity Study  
 
Cytotoxicity assays were performed using the Vero monkey kidney cell line 
(CCL-81) obtained from the American Type Culture Collection (ATCC, Manassas, VA). 
Vero cells were propagated in Dulbecco’s Modified Eagle’s Medium supplemented with 
10% fetal bovine serum and maintained in a humidified incubator (37°C, 5% CO2). After 
dislodging cells with a cell scraper, they were collected by centrifugation, resuspended in 
fresh medium at ~106 cells/mL, dispensed into 96-well microtiter plates (100 µl/well) and 
incubated for 18 h at 37°C before being used for cytotoxicity assays. Test compounds 
were subsequently added at concentrations ranging from 400-0.2 µg/mL and incubation 
continued for another 72 h before the cytopathic effects of compounds was determined 
using the MTT Cell Proliferation Assay (ATCC). The cytotoxic IC50 defined as the 
concentration causing 50% reduction in Vero cell viability, was obtained from a dose 
response curve plotted from percentage activity versus log10 concentration.   Therapeutic 
selectivity was then determined as the Cytotoxic IC50 divided by the MIC against M. 
tuberculosis. 
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CHAPTER 3: DESIGN OF NOVEL SIDEROPHORE ANTIMICROBIAL 
AGENTS FOR THE TREATMENT OF GRAM-NEGATIVE BACTERIA 
 
 
Introduction to Gram-Negative Bacteria 
 
 
Composition 
 
 Gram-negative bacterial infections are much more difficult to treat than gram-
positive bacterial infections.  This discrepancy is due to a variety of reasons that 
ultimately lead back to the fact that penetrating the gram-negative bacterial cell wall is 
very difficult for drug-like molecules when compared to gram-positive bacteria.  Gram-
negative bacteria have a unique outer membrane, a thinner peptidoglycan layer, and a 
periplasmic space between the cell wall and the membrane.  In the outer membrane, 
gram-negative bacteria have lipopolysaccharides, porin channels, and murein lipoprotein 
all of which gram-positive bacteria lack that limit permeability.112   
 
  
Quorum Sensing 
 
 Quorum sensing is a term that is used to describe the ability of a population of 
unicellular bacteria to act as a multicellular organism in a cell-density-dependent 
manner.113-115  Bacteria use small diffusible molecules to exchange information between 
the separate organisms.  These small molecules are called “quormones,” or autoinducers.  
One important class of quormones used by gram-negative bacteria is the family of N-
acylhomoserine lactones (AHLs).  The length of the acyl chain and the oxidation state of 
the AHLs provide for bacterial strain specificity in the signaling process and the 
subsequent synchronization of gene expression.116  Depending upon the pattern of 
acylation, most AHLs will diffuse freely across the bacterial cell membrane.  Upon 
reaching a critical threshold concentration, the AHLs bind to their respective receptor 
proteins triggering the expression of target genes; for example, in Vibrio fischeri, genes 
located on the lux operon are transcribed that are responsible for the production of 
bioluminescence.117 
 
 Pseudomonas aeruginosa is a common environmental microorganism that has 
obtained the ability to take advantage of weaknesses in their host’s immune system to 
become an opportunistic pathogen in humans.118  Pseudomonas aeruginosa is an 
important pathogen for patients with cystic fibrosis.  Due to the nature of cystic fibrosis, 
infections caused by Pseudomonas aeruginosa, if left untreated, in these patients is often 
fatal.  Pseudomonas aeruginosa can also manifest itself as a nosocomial infection in 
other immuno-suppressed populations, particularly in burn victims.  These infections 
cause serious complications because of their wide array of virulence mechanisms and 
high inherent antibiotic resistance to Pseudomonas aeruginosa.  These infections 
continue to become more perilous as the bacteria continues to grow and form biofilms 
that increase resistance to many antibiotics.116 
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A significant amount of research has been done over the past 10 years in 
elucidating the molecular mechanisms underlying the pathogenicity of Pseudomonas 
aeruginosa.  Two different AHLs, N-(3-oxododecanoyl)homoserin lactone (1), 
synthesized by LasI, and N-butyrylhomoserine lactone (2), synthesized by RhlI, have 
been identified as the main quorum-sensing molecules in Pseudomonas aeruginosa 
(Figure 3.1).119  Quorum sensing has been demonstrated to control the expression of other 
virulence factors as well as the formation of biofilms.120  It has been demonstrated that N-
(3-oxododecanoyl)homoserine lactone (1) itself and its tetramic acid-degradation 
product, derived from an unusual intramolecular condensation reaction, function as innate 
bactericidal agents.  Also, the AHL degradation product has been shown to tightly 
coordinate essential metals such as iron, possibly providing a previously unrecognized 
primordial siderophore.116  The iron chelating ability of tetramic acids has been proven 
and quantified.121 
 
 
Tetramic Acids 
 
 Tetramic acids are a known class of antibacterial compounds.116,122  The term was 
coined in 1901 in reference to the heterocyclic 1,5-dihydro-4-hydroxy-2H-pyrrol-2-one 
system, 3 (Figure 3.2).  This structure is a tautomer of 2,4-pyrrolidinedinone, which is the 
major tautomeric species in solution, 4 (Figure 3.2).  Compounds containing this 
functionality show a wide range of biological activity and have attracted the attention of 
medicinal chemists who hope to utilize this unique group in the design of future 
antibacterial agents.122   
 
 Naturally occurring tetramic acids have stirred up a great amount of interest due 
to their wide array of antibacterial activity.  However, there currently are not any drugs 
available on the market that contain the tetramic acid core.123,124  The tetramic core is the 
key component of many natural products such as reutericyclin, tenzuazoic acid, 
streptolydigin, PF1052, and erythroskyrine (Figure 3.3).124-127  All of these compounds 
show antibacterial activity.  Quite a few studies have been conducted on synthesizing and 
isolating naturally occurring tetramic acids.  However, only a few studies exist that report 
on the SAR of these compounds and emphasize their antibacterial properties.128-130 
 
 
Synthesis of Quorum Sensing Molecule 1 and Its Degradation Product 
 
 In order to test the iron chelating ability of the tetramic acid degradation product 
of N-(3-oxododecanoyl)homoserine lactone, both compounds were synthesized (Scheme 
3.1).116,131  Compound 1 was prepared by the DCCI/DMAP catalyzed acylation of 
Meldrum’s acid with decanoic acid in dichloromethane.  The isolated product was used in 
the next step of the reaction without further purification.  Amidation of the product with 
L-homoserine lactone in the presence of triethylamine in acetonitrile afforded the desired 
N-(3-oxododecanoyl)homoserine lactone in 9% yield.   
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Figure 3.1: Quorum Sensing Molecules 1 and 2  
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Figure 3.2: Tautomers of Tetramic Acid Moiety 
 
 
 
 
 
N
O
O
OH
O
Reutericyclin
N
H
O
O
OH
Tenuazonic Acid
O
OO
H
N
O
O
OH
H
O
NH
O
OH
Streptolydigin
O
OH
N
O
O
PF1052
N
O
O
OH
O
OH
HO
H
H
Erythroskyrine
Figure 3.3: Structures of Tetramic Acid Containing Natural Products 
62 
Scheme 3.1: Synthesis of Quorum Sensing Molecule 1 and Its Degradation Product 
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The tetramic acid degradation product of 1 was prepared by placing 1 in a flask 
containing anhydrous methanol.  To this a 0.5 molar (M) solution of sodium methoxide in 
methanol was added.  This reaction was stirred at room temperature, and then passed 
through an acidic ion-exchange resin (Dowex 50WX2-200) and eluted with methanol.  
The filtrates were combined and concentrated.  The final product was afforded after 
purification via HPLC.  The final compound was obtained in 35% yield.  
 
 
Significance of the Tetramic Acid Degradation Product as a Siderophore 
 
 Compound 1 and its tetramic acid degradation product play a pivotal in the life of 
the gram-negative bacteria Pseudomonas aeruginosa.  It has been hypothesized that due 
to the fact compound 1 is the primary quorum sensing molecule for Psuedomonas 
aeruginosa, and the fact that tetramic acids have proven antibacterial activity, the 
tetramic acid of 1 plays an important role in bacterial viability.116  One study has shown 
that lipid-like antibiotics have a propensity to localize near the cell surface on gram-
positive bacteria.132  It has been shown that when the tetramic acid of 1 is incubated 
overnight with gram-positive bacteria, significant antibacterial activity is seen.  However, 
when the same experiment is conducted with gram-negative bacteria, no antibacterial 
activity was seen.116  In analogous studies, it has been shown that structurally similar 
tetramic acids also show toxicity against gram-positive bacteria with little variation in 
EC50 value across different species and genera.133  While the antibacterial activity of this 
tetramic acid may not be as great as other known bactericidal agents, the fact that this 
compound is nonenzymatically produced from a cell-cell signaling molecule is 
significant.116   
 
These compounds were synthesized in an attempt, not to demonstrate their 
antibacterial activity, but to show the iron chelating ability of the tetramic acid in our 
hands, and its potential role as a siderophore.  It has been shown that tetramic acids have 
the ability to chelate iron in an efficient manner.  Iron has an indispensable function in 
physiological processes and pathogenesis of bacteria.134,135  Some bacteria have been 
known to synthesize a siderophore to aid in the sequestration of iron, an element that is 
essential for their growth, but is poorly soluble at physiological conditions.136  It has been 
shown that Pseudomonas aeruginosa produces two siderophores, pyoverdin and 
pyochelin, and can also utilize various heterologous siderophores of microbial origins.134  
The genome of Pseudomonas aeruginosa encodes for numerous homologues of iron-
siderophore receptor genes.  This reveals just how important iron is to bacterial survival, 
and its need to compete with other microorganisms within their environment for this 
indispensable metal.137,138   
 
 The tetramic acid iron chelate of compound 1 has been sent to collaborators at 
Northeastern University to explore its potential as a growth promoter for unculturable 
gram-negative organisms.  This group of collaborators are conducting biological 
evaluations of this compound, which are currently still in their infancy.  There has been 
some promising preliminary data that has arisen from these tests.  The collaborators 
collected intertidal sediment from Canoe Beach in Nahant, MA and air dried it to enrich 
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for spore forming microorganisms.  The 5 g of sediment was mixed with 5 mL of 2% 
Artificial Sea Salts (Sigma) and vortexed for 1 minute to remove bacterial cells from the 
sand biofilm.  Next, 100 uL samples were plated on R2A (Difco) agar supplemented with 
2% Artificial Sea Salts.  Replicates with and without spotting 10 uL of a 0.24 mg/mL 
solution of tetramic acid of compound 1 (1% DMSO in water) were incubated at room 
temperature and photographed after one and three days.   
 
 This preliminary data clearly shows that while it takes three days for most 
colonies to appear from these bacterial isolates, the largest and fastest growing colony 
appears where the tetramic acid of compound 1 was spotted (Figure 3.4).  The experiment 
was performed induplicate, and the results were identical for both runs (Figure 3.5).  This 
data shows the ability of the tetramic acid of compound 1 to presumably aid in the 
sequestration of nutrients from the environment surrounding these bacteria.  This allows 
the bacterial colony to grown larger and more rapidly than the other colonies on the 
plates.  This data clearly demonstrates the ability of bacteria to adapt and use foreign 
substances in order to provide itself with the best opportunity to survive. 
 
The 3-acetyl-pyrrolidine-2,4-dione heterocycle core found in most tetramic acid, 
including the tetramic acid of compound 1, has been shown to effectively chelate 
numerous metal cations including iron.121  It is unclear as to whether chelation with a 
metal cation alters the toxicity of this compound as some tetramic acids have shown an 
increased toxicity upon chelation while others have shown a decrease in toxicity.139  
Previous studies have demonstrated that the fungal tetramic acid metabolite tenuazoic 
acid forms an octahedral complex with a 3:1 stoichiometry upon chelation with 
iron(III).140  In accordance with these studies, it is hypothesized that the tetramic acid of 
compound 1 will have the same coordination geometry and stoichiometry.116 
 
 
Synthesis of Iron(III) Chelation Product of Tetramic Acids 
 
 The iron(III) chelation complex of tetramic acid from compound 1 was 
synthesized by dissolving three equivalents of the tetramic acid in methanol (Scheme 
3.2).  As the tetramic acid dissolved, the solution became a light tan color.  Separately, 
one equivalent of iron(III) chloride was dissolved in methanol.  This solution was bright 
yellow in color.  The solution of iron(III) chloride was then added to the solution of the 
tetramic acid and the resulting solution immediately became dark red in color.  The 
solutions were stirred at room temperature for 30 minutes, and then concentrated by 
rotary evaporation to afford a dark red viscous liquid.  The formation of the 3:1 ratio was 
confirmed via mass spectrometry and spectrophotometric assay at 440 nm.  A chelation 
complex was also synthesized for another tetramic acid derivative that was previously 
synthesized, Lee 867 (Scheme3.3).  This product was obtained utilizing the same 
synthetic procedure for the first chelation complex. 
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Figure 3.4: Preliminary Biological Evaluation of Tetramic Acid 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Repeat of Preliminary Biological Evaluation of Tetramic Acid 1 
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Scheme 3.2: Synthesis of Chelation Product for Tetramic Acid 1 
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Reagents and Conditions: (a) FeCl3, Methanol, RT, 30 minutes 
 
 
 
 
Scheme 3.3: Synthesis of Chelation Complex for Lee 867 
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Siderophores as Antibacterial Agents 
 
 
Background 
 
 As previously discussed, iron plays a vital role in the life of all bacteria.  
However, due to the nature of the element it is not readily available at physiological 
conditions.  That is due to the fact that it is rapidly oxidized from Fe2+ to Fe3+ and 
subsequently forms insoluble hydroxides.  The concentration of Fe3+ at physiological 
conditions is as low as 10-9 M, which makes this commodity very scarce for the 
bacteria.141-143  Bacteria have evolved numerous ways to overcome this shortage of 
iron.144,145  These evolutionary tactics primarily involve the formation of receptor proteins 
on the surface of the bacteria that bind to a wide range of iron-containing molecules. 
These receptors caused the iron complexes to become localized on the cell surface, where 
they then become accessible for transport inside the cell.  This process is easily carried 
out by gram-positive bacteria.  They are able to deliver the siderophore to Adenosine 
Triphosphate (ATP)-binding-cassette (ABC) importers, which transport the siderophore 
across the cell membrane.  The energy for this process comes from the hydrolysis of ATP 
inside of the cell.  A process similar to this occurs in the gram-negative bacteria, but the 
process is more convoluted due to the presence of the additional lipid layer found in these 
organisms.143   
 
Transportation of nutrients in gram-negative bacteria usually occurs via porins.  
These porins allow small molecules and ions to diffuse through the membrane.  However, 
this diffusion-driven process is inefficient for the supply of iron that is necessary for cell 
survival. The inefficiency arises primarily due to the extremely low concentration of iron 
in the surrounding environment.143 
 
 
TonB Transport System 
 
 Gram-negative bacteria have evolved a method which allows them to overcome 
the inefficiency of porin diffusion in order to obtain nutrients in a much more efficient 
manner.  This sophisticated method enables the bacteria to supply high-affinity outer-
membrane receptors with the necessary energy for ligand uptake from the cytoplasmic 
membrane by the protein complex known as the Ton system.143,146-149  This complex 
consists of numerous proteins, including TonB.  TonB is said to experience a series of 
conformational changes that are driven by the proton-motive force, which allows it 
mechanically interact with the outer-membrane receptors, thus enabling transport into the 
interior of the cell.   
 
 The importance of TonB has been validated by numerous scientific studies that 
elucidated the fact that TonB plays a vital role in nutrient transport.  These studies 
showed that TonB mutants were unable to transport siderophores or vitamin B12 into the 
cell.150,151  Another important experiment, conducted in 1980, showed that BtuC mutants, 
which are unable take up vitamin B12 across the cytoplasmic membrane, were able to 
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generate a 1000-fold increase in the concentration of vitamin B12 in the periplasmic 
space, when compared to the external medium, as long as the TonB and it energy source 
were in place.152  Therefore, while the mechanism for the TonB pathway may not be 
entirely elucidated, it is shown to play a vital role in the uptake of nutrients from the 
cellular environment.   
  
 
Application 
 
 As stated previously, there is an ever increasing need to develop novel antibiotics 
for the treatment of gram-negative bacterial infections.  Of particular concern is the 
organism Pseudomonas aeruginosa, it posses intrinsic resistance to numerous currently 
used antibiotics and it has also acquired additional mechanisms of resistance, including 
target mutations, increased expression of efflux pumps and of antibiotic-degrading 
enzymes.153  One of the biggest problems associated with treating gram-negative bacteria 
is getting the drug inside of the bacteria.  As discussed previously, gram-negative 
bacteria, Pseudomonas aeruginosa in particular, have evolved numerous ways in which 
to get nutrients from the environment into their interior for use.  Since the 1980s, 
numerous attempts have been made by drug developers to take advantage of this fact and 
utilize siderophore containing antibiotics in hopes to gain entry into the bacteria.154  One 
such agent is BAL30072 (Figure 3.6).   
 
BAL30072 is a novel siderophore monobactam antibiotic that is currently in pre-
clinical trials.  It contains a monobactam antibiotic, which is analogous to the agent 
tigemonam, and a dihydropyridone iron-chelating group.155,156  It has been shown that 
this combination of features provides markedly different antibiotic properties to 
BAL30072, along with a different mechanism of action.155,157,158  BAL30072 has shown 
activity against 70% of the carbapenem-resistant Enterobacteriaceae strains tested, 
including stains with class A, class B, and class D carbapenemases.  BAL30072 show 
promising activity against non-fermentors, especially Acinetobacter spp., Burkholderia 
spp., and Stenotrophomonas maltophila.  It was also the most active β-lactam against 
MDR-Pseudomonas aeruginosa in the panel tested.159 
 
 The promising activity shown by BAL30072 has led to the development of a 
hypothesis involving the use of a novel siderophore attached to an antibacterial agent 
(Figure 3.7).  It is thought that, as in the case of BAL30072, this siderophore will allow 
the antibacterial agent to enter the gram-negative bacteria via an alternate route with 
more efficacy than porin mediated entry, thus allowing the agent to kill the bacteria more 
effectively.  The siderophore that was chosen for this experiment was the tetramic acid 
core.  As previously shown, this core structure can readily chelate iron and therefore 
shows promise for utilization as a siderophore. 
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Figure 3.6: Structure of BAL 30072 
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Synthesis of Tetramic Acid Core 
 
 The tetramic acid core was synthesized according to a previously reported 
procedure (Scheme 3.4).124  The synthesis started with the reductive amination of valine 
ethyl ester hydrochloride salt with 3-((tert-butyldimethylsilyl)oxy)propanal in 
tetrahydrofuran in the presence of magnesium sulfate and triethylamine.  The resulting 
imine was reduced using sodium borohydride in methanol.  The secondary amine was 
then reacted with diketene in dichloromethane in the presence of triethylamine at reflux 
to yield the β-keto amide.160  The amide was then cyclized in the tetramic acid core using 
Amberlyst A-26 hydroxide resin.161,162   
 
The starting aldehyde (3-((tert-butyldimethylsilyl)oxy)propanal) is a relatively 
expensive compound.  Therefore, in order to reduce the cost associated with using this 
starting material; an alternate synthetic route was developed (Scheme 3.5).  This route 
utilizes the same valine ethyl ester hydrochloride salt, but instead of the aldehyde, (3-
bromopropoxy)(tert-butyl)dimethylsilane was used in its place.  The reaction was carried 
out in the microwave reactor in dimethylformamide in the presence of potassium 
carbonate.  Once the secondary amine was isolated, the reaction continued in the same 
manner as shown in Scheme 3.4. 
 
 This multiple-step synthetic reaction afforded the final compound and the desired 
intermediates in adequate yields.  The first step of this reaction produced the secondary 
amine intermediate in a 44% yield.  The second step afforded the amide in a 50% yield.  
The final step provided the final product in an 88% yield.  Overall these yields are 
reasonable and are high enough to provide a substantial amount of the final compound in 
a reasonable timeframe.  When attempting to couple the tetramic acid core to the desired 
antibiotic, in order to complete the desired synthesis, problems were noted and no final 
compound was obtained.  A number of different synthetic techniques were attempted, but 
none were able to afford the desired compound.  One problem may be the fact that there 
are two alcohol moieties present in the tetramic acid core.  Upon trying to couple the 
primary alcohol to the antibiotic, no reaction was observed.  This is probably due to the 
fact that the secondary alcohol may be interfering with the reaction.  In order to alleviate 
this problem, orthogonal protecting group strategies need to be explored that can provide 
selective protection for each type of alcohol present.  Upon attempting various other 
synthetic methodologies, none were able to produce the desired final compound. 
 
 
Conclusions 
 
 This project is only in its infancy, and there is much left to discover.  There is still 
much work to be done involving the use of siderophores as aids in the design of novel 
antimicrobial agents.  The large literature precedence for this type of work is very 
promising.  I feel as though the work done on this project in our hands will only help to 
further elucidate the role of siderophores, in particular the role of tetramic acids, in how 
they alter the in vitro and in vivo efficacy of antibacterial agents.  The preliminary 
biological study conducted by our collaborators at Northeastern University provides  
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Scheme 3.4: Synthesis of Tetramic Acid Core 
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much hope for our hypothesis that this particular type of siderophore will be useful in 
providing a route by which an antibiotic can easily enter the gram-negative bacteria.  It is 
obvious that much more work needs to be done in order to truly validate this study.  
However, this project appears to be headed down a path that will yield a very fruitful 
study into the intricacies of designing effective gram-negative antibacterial agents. 
  
 
Experimental Section 
 
All anhydrous solvents and starting materials were purchased from Aldrich 
Chemical Co. (Milwaukee, WI).  All reagent grade solvents used from chromatography 
were purchased from Fisher Scientific (Suwanee, GA) and flash column chromatography 
silica cartridges were obtained from Biotage Inc. (Lake Forest, VA).  The reactions were 
monitored by thin-layer chromatography (TLC) on pre-coated Merch 60 F254 silica gel 
plates and visualized using ultraviolet (UV) light (254 nm).  A Biotage FLASH column 
chromatography system was used to purify mixtures.  All 1H nuclear magnetic resonance 
(NMR) spectra were recorded on a Varian INOVA-500 spectrometer.  Chemical shifts (δ) 
are reported in parts per million relative to the residual solvent peak or internal standard 
(tetramethylsilane), and coupling constants (J) are reported in hertz (Hz).  Mass spectra 
were recorded on a Bruker Esquire liquid-chromatography mass-spectrometer using 
electrospray ionization.  Purity of the products was confirmed before testing by analytical 
reverse phase-high performace liquid chromatography on a Shimadzu high-performance 
liquid-chromatography system, and all final compounds had a purity of 95% or greater as 
determined by RP-HPLC. Gradient Conditions: solvent A (0.1% Trifluoroacetic Acid 
(TFA) in water) and solvent B (acetonitrile): 0-2.00 min 100& A, 2.00-7.00 min 0-100% 
B (linear gradient), 7.00-8.00 min 100% B, UV detection at 254 nm.   
 
N-(3-oxododecanoyl)-l-homoserine lactone (1).  To an anhydrous dichloromethane 
solution (20 mL) containing decanoic acid (0.57 mL, 4 mmol) was added 4-
(dimethylamino)pyridine (0.513 g, 4.2 mmol), N,N’-dicyclohexylcarbodiimide (0.907 g, 
4.4 mmol), and Meldrum’s acid (0.576 g, 4 mmol).  This solution was stirred at room 
temperature overnight and then filtered to remove the precipitated N,N’-
dicyclohexylurea.  The filtrate was evaporated to dryness, and the residue was 
redissolved in ethyl acetate.  The ethyl acetate solution was washed with 2 M 
hydrochloric acid, dried over anhydrous magnesium sulfate, and concentrated to afford 
the acylated Meldrum’s acid, which was used without purification in the next step of the 
reaction.  To a stirred solution of the acylated Meldrum’s acid (1.05 g, 3.5 mmol) in 
acetonitrile (30 mL) was added to l-homserine lactone hydrochloride (0.482 g, 3.5 mmol) 
and triethylamine (0.585 mL, 4.2 mmol).  The mixture was stirred at room temperature 
for 2 hours and then heated under reflux conditions for 3 hours.  The solvent was 
removed by rotary evaporation to give a residue that was redissolved in ethyl acetate.  
The organic solution was subsequently washed with saturated sodium hydrogen 
carbonate solution, 1 M potassium hydrogen sulfate solution, and saturated sodium 
chloride solution.  After drying over anhydrous magnesium sulfate, the organic solution 
was evaporated and the residue was purified flash chromatography using a hexanes to 
ethyl acetate gradiant to afford pure 1 (0.108 g, 9%).  1H NMR (CDCl3): δ 0.88 (3H, t, J 
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= 7.5 Hz), 1.26 (12 H, m), 1.59 (2H, m), 2.24 (1H, pentet, J = 11 Hz), 2.53 (2H, t, J = 7.5 
Hz), 2.75 (1H, pentet, J = 1.5 Hz), 3.50 (2H, s), 4.28 (1H, m), 4.48 (1H, t, J = 8 Hz), 4.59 
(1H, m), 7.75 (1H, s).  RP-HPLC: tR = 7.68 min. ESI-MS m/z: 320.2 [M + Na]+.  
 
3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione (Tetramic Acid of 
1).  To a flask containing N-(3-oxododecanoyl)-l-homoserine lactone (0.090 g, 0.3026 
mmol) in anhydrous methanol (1 mL), sodium methoxide in methanol (0.5 M, 0.605 mL, 
0.3026 mmol) was added at room temperature under argon.  After stirring at 55 degrees C 
for three hours, the reaction mixture was passed through acidic ion-exchange resin 
(DOWEX 50WX2-200) and eluted with methanol (20 mL).  The combined filtrates were 
concentrated on a rotary evaporated to give a residue.  The resulting residue was purified 
using RP-HPLC to afford pure compound (0.020 g, 22%).  1H NMR (CD3OD): δ 0.90 
(3H, t, J = 7.0 Hz), 1.23-1.43 (12 H, m), 1.66 (2H, m), 1.72-1.83 (1H, m), 1.96-2.10 (1H, 
m), 2.70-2.92 (2H, m), 3.61-3.79 (2H, m), 3.99 (1H, s).  RP-HPLC: tR = 6.708 min. ESI-
MS m/z: 320.1 [M + Na]+. 
 
Iron(III) Chelate of 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-
dione.  A small round-bottom flask containing 3-(1-hydroxydecylidene)-5-(2-
hydroxyethyl)pyrrolidine-2,4-dione (0.050 g, 0.168 mmol) in methanol (1 mL) was 
stirred at room temperature for 5 minutes.  A separate round-bottom flask containing 
iron(III) chloride (0.0091 g, 0.056 mmol) in methanol (1 mL) was stirred at room 
temperature for 5 minutes.  The solution of iron(III) chloride was then added to the flask 
containing the solution of 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-
dione and this was allowed to stir at room temperature for 30 minutes.  The content of the 
flask was then concentrated to afford pure compound.  ESI-MS m/z: 947.49 [M + 3H]+. 
 
Iron(III) Chelate of Lee 867.  A small round-bottom flask containing Lee 867 (0.0725 
g, 0.215 mmol) in methanol (1 mL) was stirred at room temperature for 5 minutes.  A 
separate round-bottom flask containing iron(III) chloride (0.012 g, 0.072 mmol) in 
methanol (1 mL) was stirred at room temperature for 5 minutes.  The solution of iron(III) 
chloride was then added to the flask containing the solution of Lee 867 and this was 
allowed to stir at room temperature for 30 minutes.  The content of the flask was then 
concentrated to afford pure compound.  ESI-MS m/z: 1068.31 [M + 3H]+. 
 
(Z)-3-(1-hydroxyethylidene)-1-(3-hydroxypropyl)-5-isopropylpyrrolidine-2,4-dione 
(Tetramic Acid Core).  To a stirred solution of valine ethyl ester hydrochloride (0.408 g, 
2.65 mmol) in tetrahydrofuran was added magnesium sulfate (0.543 g, 4.51 mmol), 3-
((tert-butyldimethylsilyl)oxy)propanal (1 g, 5.31 mmol), and triethylamine (0.37 mL, 
2.65 mmol).  The reaction was then allowed to stir at room temperature under argon for 
five hours.  The reaction mixture was then filtered and the eluent evaporated to give the 
crude imine intermediate.  The imine was directly redisolved in methanol, and sodium 
borohydride (0.20 g, 5.31 mmol) was slowly added to the reaction mixture.  The reaction 
was stirred at room temperature for 30 minutes before being quenched with excess 1 N 
sodium hydroxide and extracted with ethyl acetate.  The ethyl acetate extracts were 
combined, washed with brine, and dried over sodium sulfate.  The extracts were then 
concentrated under vacuum.  The residue was purified by flash chromatography using a 
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petroleum ether to ethyl acetate gradient.  The purified intermediate (0.340 g, 1.17 mmol) 
was then dissolved in dichloromethane.  To this solution diketene (0.084 mL, 1.17 mmol) 
and five drops of triethylamine were added.  The resulting solution was then heated under 
reflux conditions for six hours.  The reaction mixture was then cooled, diluted with 
dichloromethane and washed with dilute hydrochloric acid followed by water.  The 
dichloromethane fractions were then dried over sodium sulfate and concentrated.  This 
intermediate was then purified with flash chromatography using a petroleum ether to 
ethyl acetate gradient.  This intermediate (0.238 g, 0.593 mmol) was then dissolved in 
methanol.  To this solution Amberylyst A-26 resin (4.2 mequiv/g, 3 equiv) was added.  
The reaction was stirred at room temperature under agron for two hours.  The product 
containing resin was then filtered and washed with methanol (3 x 10 mL).  The resin was 
then stirred at room temperature for 30 minutes in methanol (10 mL) with TFA (400 µL).  
It was then filtered and washed with methanol.  Concentration of the eluent afforded pure 
product (0.126 g, 88%).  1H NMR (CDCl3): δ 0.93 (6H, d, J = 7.0 Hz), 1.71-1.77 (2H, 
m), 2.05 (2.2H, s), 2.20 (0.8H, s), 2.64 (1H, m), 2.95 (2H, m), 3.52-3.60 (3H, m), 4.45 
(1H, d, J = 7.0 Hz).  RP-HPLC: tR = 6.13 min. ESI-MS m/z: 264.3 [M + Na]+. 
 
 
75 
CHAPTER 4: OVERALL DISCUSSION OF DISSERTATION 
 
 
Introduction 
 
 The two projects discussed in this dissertation deal with the development of novel 
antimicrobial agents.  These projects play a vital role in the need for continuing research 
into ways to help combat the ever increasing rise of bacterial resistance.  As bacteria 
continue to evolve new resistant mechanisms, every piece of research into the 
development of new ways to treat bacterial infections becomes crucial.  The projects I 
have worked on both involved bacteria, but each focused on a different type of bacteria.  
The first project I worked on focused on new ways to treat infections caused by 
Mycobacterium tuberculosis.  The threat caused by the bacteria is growing, and 
discovering novel agents with novel mechanisms of action is becoming a very high 
priority among the scientific community.  My second project involved the design of novel 
treatment for gram-negative bacterial infections.  These organisms are becoming 
increasingly resistant to the antibiotics that are currently on the market, and therefore new 
agents are desperately needed.  The pipeline for combating these agents is sparse, and 
more focus needs to be placed on this area by the pharmaceutical industry.  The purpose 
of this chapter is to provide a look into the key aspects of each project and to discuss 
potential future endeavors that can keep these projects fruitful. 
 
 
Urea Project 
 
 This project was discussed in Chapter 2 of this dissertation.  It dealt with the 
discovery of novel agents to help combat the increasing threat of multi- and extensively-
drug resistant tuberculosis.  The agents synthesized in this chapter all possess a novel 
mechanism of action that can be exploited to avoid resistance associated with current 
therapies for tuberculosis.  This project originated through the use of a current medicinal 
chemistry technique that allows for the discovery of a small number of active compounds 
within a large collection of compounds called high-throughput screening.  Through this 
process, the hit compound was discovered and selected for further modification. 
 
 The modifications chosen for this compound centered on the idea of obtaining a 
complete SAR for this series of compounds.  The first modifications made to the hit 
compound involved changing the bulky aliphatic moiety while keeping the 
trifluorophenyl group constant.  A variety of bulky aliphatic groups were chosen to 
replace the adamantyl moiety.  These modifications, for the most part, led to compounds 
with activity that was comparable to the parent compound.  The compounds that lost 
activity were compounds that contained groups that were not a bulky as the original 
adamantyl group.   
 
 The next set of modifications involved the changing of the trifluorophenyl moiety 
for other aromatic rings while holding the adamantyl position constant.  These 
modifications seemed to all provide compounds with similar activity to the parent 
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compound.  All of the groups tested in this set appeared to be well tolerated as the worst 
MIC for a compound in this set was 3.125 µg/mL. 
 
 The next modifications involved holding the adamantyl constant and replacing the 
aromatic ring with various non-aromatic groups consisting primarily of alkyl chains with 
varying lengths.  The majority of these compounds showed poor activity.  There were a 
few exceptions that showed activity comparable to the parent compounds, but these are 
not candidates for further evaluation due to their poor drugability.   
 
 Modifications were made that also involved changing both sides simultaneously 
so that the only remaining identifier of the parent compound was the urea moiety.  These 
compounds showed activity similar to the parent compounds, but none produced activity 
that was better than the parent compound.   
 
 In order to complete the SAR study, it was crucial to make modifications to the 
urea moiety itself.  This was done using the parent compound.  The urea moiety was 
modified four different ways; (1) the carbonyl oxygen was replaced with a sulfur to make 
a thiourea, (2) one of the nitrogen atoms was replaced with an oxygen to form a 
carbamate, (3) one hydrogen atom attached to one of the nitrogen atoms was replaced 
with a methyl group, (4) both hydrogen atoms on the nitrogen atoms were replaced with 
methyl groups.  These modifications produced a very clear and well defined SAR 
concerning the urea moiety.  As the modifications progress, from the parent compound, 
the activity incrementally decreases with each modification.  Replacement of the oxygen 
atom with sulfur decreased the MIC from 0.01 µg/mL to 0.8 µg/mL.  This decrease 
inactivity can possible be related to the fact that sulfur is a larger atom than oxygen and 
this could disrupt parts of the hydrogen bonding network found in the active site.  
Replacement of a nitrogen atom with oxygen and methylation of one nitrogen atom both 
decreased the MIC to 6 µg/mL.  This appears to be due to the loss of the hydrogen atom 
as a hydrogen bond donor to amino acid residues within the active site.  Finally, 
methylation of both nitrogen atoms resulted in an MIC of 12 µg/mL.  This is follows the 
previously mentioned hypothesis in that both hydrogen bond donating hydrogen atoms 
have now been replaced.   
 
 This project, while producing compounds with excellent activity against 
Mycobacterium tuberculosis, is not without faults.  The compounds that have been 
submitted for in vivo efficacy testing have not shown favorable results.  This is more than 
likely due to the high lipophilicity of these compounds.  The next generation of these 
compounds should focus on reducing the lipophilicity of these compounds in an effort to 
improve their in vivo efficacy.  The lead compound for this series has been identified as 
compound 36 in Table 2.3.  The compounds in this table were synthesized in an effort to 
reduce the lipophilicity of this series.  However, the majority of the compounds 
synthesized showed a decrease in activity and were not acceptable for further 
optimization.  Compound 36 retained respectable activity and is less lipohilic.  It has 
shown to be orally bioavailable.107,163 
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 This series of compounds is also riddled with another hindrance.  There is a 
human form of the epoxide hydrolase enzyme, and these compounds need to selectively 
inhibit the Mycobacterium tuberculosis form of the enzyme without interfering with the 
human enzyme.  Compound 36 may help with the lipophilicity issues associated with 
these compounds, but it is also a known human epoxide hydrolase inhibitor.  The next 
generation of these compounds will need to be modified in a way that selectivity for 
Mycobacterium tuberculosis can be achieved.  There have already been three general 
scaffolds identified that will be the future direction of this project (Figure 4.1).  The 
continuation of this project is already underway by a fellow member of the Lee Lab, and 
the results will be reported in due time.   
 
 
Tetramic Acid Project 
 
 This project is discussed in Chapter 3 of this dissertation.  This project is truly in 
its infancy.  I have undertaken a lot of literature study with this project in an effort to 
fully understand the scope of this project.  I also set out to synthesize a few final 
compounds for this project, but ultimately I was unsuccessful in synthesizing a complete 
siderophore antibacterial agent.  Although, I was not able to fully complete the synthesis 
of on the desired compounds, this project should remain a focus in the Lee Lab due to the 
potential it presents. 
 
The potential of this project to be high impact is evident from the literature 
precedence seen during my searches.  It is shown in the pre-clinical candidate, 
BAL30072, that the idea of attaching a siderophore to an antibacterial agent in an effort 
to increase its efficacy is a valid hypothesis.  Also, the initial experiments done by our 
collaborators at Northeastern University show that the iron chelated tetramic acid of the 
quorum sensing molecule synthesized in Scheme 3.1 helps an unknown microorganism 
grow more abundantly and may be used as a growth enhancer for unknown 
microorganisms.  This is postulated to be due to the fact that the microorganism is 
utilizing the tetramic acid to aid in its uptake of iron from the environment.  The novel 
siderophore used in our laboratory, the tetramic acid core, has numerous points of 
diversity which can allow us to alter the structural diversity of this moiety in order to 
ensure optimal activity.   
 
The possibilities for this project seem to really cover a wide spectrum.  In my 
synthetic attempts during this project I was attempting to connect the tetramic acid 
molecule synthesized in Scheme 3.4 to a cephalosporin antibiotic (Figure 4.2)  However, 
this is just the beginning of the possibilities for this type of compound.  The direction of 
this project is ultimately to see improved efficacy of gram-negative agents so as to help 
alleviate burden associated with gram-negative infections.  It would be interesting to see 
the change in activity associated with attaching this class of siderophore to a variety of 
antibacterial agents. 
 
It would be very interesting to see if by taking an agent that only shows activity 
against gram-positive bacteria, then attaching this class of siderophore, you can impart  
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Figure 4.1: Structures for Future Direction of Urea Project 
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gram-negative activity as well.  Also, the idea of taking an agent that was initially 
designed to be active against gram-negative bacteria, but showed no activity in vivo, and 
attaching this class of siderophore to see if any gram-negative activity can be obtained. 
 
One of the shortcomings of this project at this time is that I have not been able to 
successfully synthesize a compound from which data can be extracted.  Therefore, one of 
the issues appears to be that the chemistry associated with coupling the tetramic acid 
moiety and the antibiotic of choice is difficult.  The yield obtained from the synthesis of 
the tetramic acid compound is also low, and thus there is room for improvement in that 
aspect.  The development of new synthetic schemes should be a top priority as this 
project progresses into the future in an effort to overcome these shortcomings.  If these 
issues can be overcome, or at least attenuated, then the future of this project appears to be 
very fruitful for the discovery of novel antibacterial agents.   
 
 
Final Thoughts 
 
 During my tenure in graduate school, I have had the pleasure of being able to 
conduct cutting edge research in an area that shows a clear need for new development.  
Although my training has been as a synthetic chemist, my educational experience has 
allowed me to become a well-rounded scientist.  The idea of being more than just a 
chemist is what initially attracted me to the field of medicinal chemistry.  I realized that I 
wanted to be in a field where the implications of my research can be seen and understood 
immediately.  The fact that one day I can synthesize a compound in the laboratory, then 
have it tested in an in vitro system, and then determine the next course of action really 
shows how the field of medicinal chemistry can and has changed the way that bacterial 
infections are treated.  
 
Medicinal chemistry is a very interdisciplinary science.  It utilizes knowledge 
from a variety of scientific fields in order to effectively create a well-rounded scientist.  
Working as a medicinal chemist involves working in an interdisciplinary environment 
where collaboration is the key to success.  Training as a medicinal chemist can differ 
depending upon one’s experience and interests, but in the end a medicinal chemist is a 
person who can bridge some of the gaps between chemistry and biology.  This ability 
makes a well-trained medicinal chemist an invaluable asset to any interdisciplinary 
research team.  Interdisciplinary training should be included as a requirement in all 
science-based Ph.D. training.  Such a concept would lead to a better understanding of the 
overall connectivity of science between fields and ultimately produce more well-rounded 
scientists.   
 
 The projects that I have worked on during my time in graduate school have been 
projects that serve a purpose.  They have afforded me ample hands-on experience in the 
chemistry laboratory.  I have had the opportunity to expand my knowledge base on a 
variety of different synthetic techniques.  In addition to my expanded chemistry 
knowledge, I have been able to grow my knowledge on the biological significance for 
these projects.  These projects allowed me to build up a significant knowledge base on 
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the infectious agents associated with these projects; Mycobacterium tuberculosis and 
gram-negative infections.  The ability to work on projects that required me to expand my 
knowledge has really benefited me in my quest to become a well-rounded scientist.  It is 
my goal to continue to grow my knowledge base for each project that I undertake during 
my professional career.   
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